SherryVJ的个人主页 - 老虎社区

SherryVJ

SherryVJ

seraph & smiles!

IP属地：未知

379关注

104粉丝

0主题

0勋章

2021-08-04

[Tongue]

Stocks open slightly lower after ADP private-sector payrolls data<blockquote>ADP 私营部门就业数据公布后，股市小幅开盘走低</blockquote>

2021-09-17

🥰🥰🥰🥰

Zoom Video Stock rose 2% in morning trading<blockquote>Zoom Video股价早盘上涨 2%</blockquote>

2021-12-03

Good

Moderna stock jumped more than 5% in premarket trading<blockquote>Moderna 股价在盘前交易中上涨超过 5%</blockquote>

2021-11-15

$SINGAPORE EXCHANGE LIMITED(S68.SI)$Ddd

2021-09-24

Ok

Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote>

2021-09-09

All Red ( Red is the colour of luck) 💋💋💋

Most of China concepts stocks fell in premarket trading<blockquote>大多数中国概念股在盘前交易中下跌</blockquote>

2021-09-04

Thanks ☺️

抱歉，原内容已删除

2021-08-30

Tell me your opinion about this news...

抱歉，原内容已删除

2021-08-13

Tell me your opinion about this news...

Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote>

2021-08-12

Need support to more online 😬

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3586426326873853","uuid":"3586426326873853","gmtCreate":1623381375220,"gmtModify":1628402107333,"name":"SherryVJ","pinyin":"sherryvj","introduction":"","introductionEn":"","signature":"seraph  & smiles!","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":104,"headSize":379,"tweetSize":373,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.14%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.77%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":699146410,"gmtCreate":1639759405628,"gmtModify":1639760513920,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Tiger","listText":"Tiger","text":"Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699146410","repostId":"1113440959","repostType":4,"repost":{"id":"1113440959","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752802,"share":"https://www.laohunote.com/m/news/1113440959?lang=zh_CN&edition=full","pubTime":"2021-12-17 22:53","market":"us","language":"en","title":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%<blockquote>电动汽车股早盘大幅下跌，Rivian下跌 12%，Lucid Group 下跌 7%，通用汽车下跌 5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113440959","media":"Tiger Newspress","summary":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown","content":"<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown&nbsp;Motors&nbsp;sliding&nbsp;6%&nbsp;and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p><p><blockquote>电动汽车股在早盘交易中大幅下跌，Rivian下跌 12%，Lucid Group 下跌 7%，Lordstown Motors 下跌 6%，通用汽车下跌 5%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%<blockquote>电动汽车股早盘大幅下跌，Rivian下跌 12%，Lucid Group 下跌 7%，通用汽车下跌 5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%<blockquote>电动汽车股早盘大幅下跌，Rivian下跌 12%，Lucid Group 下跌 7%，通用汽车下跌 5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-17 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown&nbsp;Motors&nbsp;sliding&nbsp;6%&nbsp;and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p><p><blockquote>电动汽车股在早盘交易中大幅下跌，Rivian下跌 12%，Lucid Group 下跌 7%，Lordstown Motors 下跌 6%，通用汽车下跌 5%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","GM":"通用汽车","RIVN":"Rivian Automotive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113440959","content_text":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.","news_type":1,"symbols_score_info":{"RIVN":0.9,"GM":0.9,"LCID":0.9,"RIDE":0.9}},"isVote":1,"tweetType":1,"viewCount":4490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607438496,"gmtCreate":1639576827511,"gmtModify":1639576828652,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;","listText":"[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;[Shy]&nbsp;","text":"[Shy] [Shy] [Shy] [Shy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607438496","repostId":"1148643584","repostType":4,"repost":{"id":"1148643584","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639575903,"share":"https://www.laohunote.com/m/news/1148643584?lang=zh_CN&edition=full","pubTime":"2021-12-15 21:45","market":"us","language":"en","title":"U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation<blockquote>由于美国人面临高通胀，美国 11 月份零售额温和攀升 0.3%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148643584","media":"Tiger Newspress","summary":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at","content":"<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p><p><blockquote><b>数字：</b>亚马逊、塔吉特和其他零售商在假期开始时公布，11 月份的销售额小幅增长了 0.3%，但如果考虑到高通胀，收入在经济疲软的情况下下降。</blockquote></p><p> Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p><p><blockquote>《华尔街日报》调查的经济学家预测增长0.8%。</blockquote></p><p> The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly&nbsp;rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p><p><blockquote>销售额的增长被生活费用的上涨所抵消。11月份消费者价格指数上涨0.8%，推动年通货膨胀率达到6.8%的39年来最高水平<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a>经通货膨胀调整后，零售额似乎有所下降。</blockquote></p><p> <b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p><p><blockquote><b>大局：</b>由于刺激资金、工资上涨以及疫情期间积累的大量储蓄，美国人有很多钱可以花。但飙升的通货膨胀可能会让他们重新考虑购买什么。</blockquote></p><p> The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p><p><blockquote>最大的危险是，如果高通胀持续存在，物价上涨根深蒂固于经济之中。这可能迫使美联储提高利率，进一步提高商业成本，并阻止消费者购买尽可能多的商品和服务。</blockquote></p><p> The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p><p><blockquote>美联储仍然相信通胀将在 2022 年降温，但央行非常担心，会比计划更快地逐步取消经济刺激措施。</blockquote></p><p> <b>Market reaction:</b>&nbsp;The Dow Jones Industrial Average&nbsp;and S&amp;P 500 were set to open slightly lower in Wednesday trades.</p><p><blockquote><b>市场反应：</b>道琼斯工业平均指数和标普500指数周三开盘小幅走低。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation<blockquote>由于美国人面临高通胀，美国 11 月份零售额温和攀升 0.3%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. retail sales climb tepid 0.3% in November as Americans confront high inflation<blockquote>由于美国人面临高通胀，美国 11 月份零售额温和攀升 0.3%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-15 21:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p><p><blockquote><b>数字：</b>亚马逊、塔吉特和其他零售商在假期开始时公布，11 月份的销售额小幅增长了 0.3%，但如果考虑到高通胀，收入在经济疲软的情况下下降。</blockquote></p><p> Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p><p><blockquote>《华尔街日报》调查的经济学家预测增长0.8%。</blockquote></p><p> The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly&nbsp;rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p><p><blockquote>销售额的增长被生活费用的上涨所抵消。11月份消费者价格指数上涨0.8%，推动年通货膨胀率达到6.8%的39年来最高水平<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a>经通货膨胀调整后，零售额似乎有所下降。</blockquote></p><p> <b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p><p><blockquote><b>大局：</b>由于刺激资金、工资上涨以及疫情期间积累的大量储蓄，美国人有很多钱可以花。但飙升的通货膨胀可能会让他们重新考虑购买什么。</blockquote></p><p> The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p><p><blockquote>最大的危险是，如果高通胀持续存在，物价上涨根深蒂固于经济之中。这可能迫使美联储提高利率，进一步提高商业成本，并阻止消费者购买尽可能多的商品和服务。</blockquote></p><p> The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p><p><blockquote>美联储仍然相信通胀将在 2022 年降温，但央行非常担心，会比计划更快地逐步取消经济刺激措施。</blockquote></p><p> <b>Market reaction:</b>&nbsp;The Dow Jones Industrial Average&nbsp;and S&amp;P 500 were set to open slightly lower in Wednesday trades.</p><p><blockquote><b>市场反应：</b>道琼斯工业平均指数和标普500指数周三开盘小幅走低。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148643584","content_text":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.\n\nEconomists polled by The Wall Street Journal had forecast a 0.8% increase.\nThe increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly rate of inflation to a 39-year high of 6.8%. Adjusted for inflation retail sales appeared to have declined.\nBig picture: Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.\nThe big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.\nThe Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.\nMarket reaction: The Dow Jones Industrial Average and S&P 500 were set to open slightly lower in Wednesday trades.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":3807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604535094,"gmtCreate":1639409933242,"gmtModify":1639411184498,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Oh my con","listText":"Oh my con","text":"Oh my con","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604535094","repostId":"1167465214","repostType":4,"repost":{"id":"1167465214","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639406352,"share":"https://www.laohunote.com/m/news/1167465214?lang=zh_CN&edition=full","pubTime":"2021-12-13 22:39","market":"us","language":"en","title":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share<blockquote>辉瑞以每股 100 美元收购 Arena Pharmaceuticals，早盘交易中股价上涨超过 80%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167465214","media":"Tiger Newspress","summary":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.Pfi","content":"<p>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.<img src=\"https://static.tigerbbs.com/baca4cde05c414b1c77aa618108489b1\" tg-width=\"774\" tg-height=\"568\" width=\"100%\" height=\"auto\">Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.</p><p><blockquote>辉瑞以每股 100 美元的价格收购了 Arena Pharmaceuticals，该公司在早盘交易中股价上涨超过 80%。辉瑞公司周一表示，已同意以 67 亿美元的全现金交易收购 Arena Pharmaceuticals，以扩大其癌症和炎症性疾病治疗产品线。</blockquote></p><p> Pfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.</p><p><blockquote>辉瑞将以每股 100 美元的价格收购 Arena 的所有流通股，较 Arena 最新收盘价溢价 100.2%。</blockquote></p><p> Arena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.</p><p><blockquote>Arena正在为胃肠病学、皮肤病学和心脏病学开发几种治疗方法。该药物开发商的溃疡性结肠炎治疗候选药物依曲莫德正处于后期研究阶段。</blockquote></p><p> Pfizer said it expects to finance the transaction with cash on hand.</p><p><blockquote>辉瑞表示，预计将用手头现金为这笔交易提供资金。</blockquote></p><p> Pfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.</p><p><blockquote>辉瑞此次交易的财务顾问是美国银行证券和 Centerview Partners LLC，古根海姆证券有限责任公司和 Evercore Group LLC 为 Arena 提供咨询服务。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share<blockquote>辉瑞以每股 100 美元收购 Arena Pharmaceuticals，早盘交易中股价上涨超过 80%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share<blockquote>辉瑞以每股 100 美元收购 Arena Pharmaceuticals，早盘交易中股价上涨超过 80%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-13 22:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.<img src=\"https://static.tigerbbs.com/baca4cde05c414b1c77aa618108489b1\" tg-width=\"774\" tg-height=\"568\" width=\"100%\" height=\"auto\">Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.</p><p><blockquote>辉瑞以每股 100 美元的价格收购了 Arena Pharmaceuticals，该公司在早盘交易中股价上涨超过 80%。辉瑞公司周一表示，已同意以 67 亿美元的全现金交易收购 Arena Pharmaceuticals，以扩大其癌症和炎症性疾病治疗产品线。</blockquote></p><p> Pfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.</p><p><blockquote>辉瑞将以每股 100 美元的价格收购 Arena 的所有流通股，较 Arena 最新收盘价溢价 100.2%。</blockquote></p><p> Arena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.</p><p><blockquote>Arena正在为胃肠病学、皮肤病学和心脏病学开发几种治疗方法。该药物开发商的溃疡性结肠炎治疗候选药物依曲莫德正处于后期研究阶段。</blockquote></p><p> Pfizer said it expects to finance the transaction with cash on hand.</p><p><blockquote>辉瑞表示，预计将用手头现金为这笔交易提供资金。</blockquote></p><p> Pfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.</p><p><blockquote>辉瑞此次交易的财务顾问是美国银行证券和 Centerview Partners LLC，古根海姆证券有限责任公司和 Evercore Group LLC 为 Arena 提供咨询服务。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARNA":"阿里那","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167465214","content_text":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.\nPfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.\nArena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.\nPfizer said it expects to finance the transaction with cash on hand.\nPfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.","news_type":1,"symbols_score_info":{"ARNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605500439,"gmtCreate":1639186173290,"gmtModify":1639186174334,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605500439","repostId":"1199826178","repostType":4,"isVote":1,"tweetType":1,"viewCount":3407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605500663,"gmtCreate":1639186160836,"gmtModify":1639186161876,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"✅&nbsp;","listText":"✅&nbsp;","text":"✅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605500663","repostId":"2190767366","repostType":4,"isVote":1,"tweetType":1,"viewCount":3178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605857916,"gmtCreate":1639147777266,"gmtModify":1639147778334,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605857916","repostId":"1100115506","repostType":4,"repost":{"id":"1100115506","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639138188,"share":"https://www.laohunote.com/m/news/1100115506?lang=zh_CN&edition=full","pubTime":"2021-12-10 20:09","market":"us","language":"en","title":"Some vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100115506","media":"Tiger Newspress","summary":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell","content":"<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p><p><blockquote>一些疫苗股在盘前交易中下跌。Moderna下跌超过6%，BioNTech和Novavax下跌约2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 20:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p><p><blockquote>一些疫苗股在盘前交易中下跌。Moderna下跌超过6%，BioNTech和Novavax下跌约2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100115506","content_text":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.","news_type":1,"symbols_score_info":{"NVAX":0.9,"MRNA":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":3251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605854787,"gmtCreate":1639147765076,"gmtModify":1639147766866,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Down&nbsp;","listText":"Down&nbsp;","text":"Down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605854787","repostId":"1148141788","repostType":4,"repost":{"id":"1148141788","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639147224,"share":"https://www.laohunote.com/m/news/1148141788?lang=zh_CN&edition=full","pubTime":"2021-12-10 22:40","market":"us","language":"en","title":"Vaccine stocks dropped in morning trading<blockquote>疫苗股早盘交易中下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148141788","media":"Tiger Newspress","summary":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","content":"<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p><p><blockquote>疫苗股在早盘交易中下跌。Moderna、BioNTech 和 Novavax 下跌 2% 至 11%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks dropped in morning trading<blockquote>疫苗股早盘交易中下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks dropped in morning trading<blockquote>疫苗股早盘交易中下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 22:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p><p><blockquote>疫苗股在早盘交易中下跌。Moderna、BioNTech 和 Novavax 下跌 2% 至 11%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148141788","content_text":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","news_type":1,"symbols_score_info":{"BNTX":0.9,"NVAX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3217,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602484310,"gmtCreate":1639058002940,"gmtModify":1639058940759,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Go&nbsp;","listText":"Go&nbsp;","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602484310","repostId":"1129645066","repostType":4,"repost":{"id":"1129645066","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639053071,"share":"https://www.laohunote.com/m/news/1129645066?lang=zh_CN&edition=full","pubTime":"2021-12-09 20:31","market":"us","language":"en","title":"Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129645066","media":"Tiger Newspress","summary":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 b","content":"<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>在意大利反垄断机构因涉嫌滥用市场支配地位对亚马逊处以 11.3 亿欧元罚款后，亚马逊股价在盘前交易中小幅下跌 0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，因涉嫌滥用市场支配地位，已对电子商务巨头亚马逊处以 11.3 亿欧元（12.8 亿美元）的罚款。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一点来鼓励活跃在亚马逊上的卖家采用自己的物流服务——亚马逊履行（FBA）。这损害了竞争对手提供的物流服务运营商，以及加强自己的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>该反垄断机构表示，将对亚马逊采取纠正措施，并接受监控受托人的审查。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌 0.5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-09 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>在意大利反垄断机构因涉嫌滥用市场支配地位对亚马逊处以 11.3 亿欧元罚款后，亚马逊股价在盘前交易中小幅下跌 0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，因涉嫌滥用市场支配地位，已对电子商务巨头亚马逊处以 11.3 亿欧元（12.8 亿美元）的罚款。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一点来鼓励活跃在亚马逊上的卖家采用自己的物流服务——亚马逊履行（FBA）。这损害了竞争对手提供的物流服务运营商，以及加强自己的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>该反垄断机构表示，将对亚马逊采取纠正措施，并接受监控受托人的审查。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129645066","content_text":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.\n\nItaly's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.\nIn a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.\n\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.\nThe antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":4212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602915546,"gmtCreate":1638956253196,"gmtModify":1638956689133,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Woo","listText":"Woo","text":"Woo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602915546","repostId":"1136716851","repostType":4,"repost":{"id":"1136716851","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638955203,"share":"https://www.laohunote.com/m/news/1136716851?lang=zh_CN&edition=full","pubTime":"2021-12-08 17:20","market":"us","language":"en","title":"Some Vaccine stocks corrected in premarket trading<blockquote>部分疫苗股盘前交易回调</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136716851","media":"Tiger Newspress","summary":"Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell betwe","content":"<p>Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech&nbsp;SE,Moderna&nbsp;and&nbsp;Pfizer&nbsp;fell&nbsp;between 3% and 7%.</p><p><blockquote>一些疫苗股在盘前交易中回调。Novavax、BioNTech SE、Moderna 和辉瑞下跌 3% 至 7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b5fc2db6a961be0363c3be880585ad0f\" tg-width=\"404\" tg-height=\"241\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Vaccine stocks corrected in premarket trading<blockquote>部分疫苗股盘前交易回调</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Vaccine stocks corrected in premarket trading<blockquote>部分疫苗股盘前交易回调</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 17:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech&nbsp;SE,Moderna&nbsp;and&nbsp;Pfizer&nbsp;fell&nbsp;between 3% and 7%.</p><p><blockquote>一些疫苗股在盘前交易中回调。Novavax、BioNTech SE、Moderna 和辉瑞下跌 3% 至 7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b5fc2db6a961be0363c3be880585ad0f\" tg-width=\"404\" tg-height=\"241\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136716851","content_text":"Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell between 3% and 7%.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606504712,"gmtCreate":1638890080088,"gmtModify":1638890089373,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"999","listText":"999","text":"999","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606504712","repostId":"1107798974","repostType":4,"repost":{"id":"1107798974","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638889130,"share":"https://www.laohunote.com/m/news/1107798974?lang=zh_CN&edition=full","pubTime":"2021-12-07 22:58","market":"us","language":"en","title":"777 Partners Orders 30 Additional 737 MAX Airplanes<blockquote>777 合作伙伴订购 30 架额外 737 MAX 飞机</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107798974","media":"Tiger Newspress","summary":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners","content":"<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p><p><blockquote>在收到 777 合作伙伴额外订购 30 架 737 MAX 喷气式飞机后，波音公司股价延续反弹势头。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Boeing&nbsp;and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p><p><blockquote>波音公司和 777 Partners 今天宣布，这家总部位于迈阿密的投资公司将通过额外购买 30 架喷气式飞机，将其 737 MAX 订单量增加近一倍。新订单将 777 Partners 的商用飞机产品组合扩大到总共 68 架 737 MAX，这是其今年第四次订购节能单通道喷气式飞机。该订单按标价计算价值 37 亿美元，将使 777 合作伙伴能够在其附属全球低成本航空公司的机队中扩大 737 MAX 业务。</blockquote></p><p> \"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p><p><blockquote>777 Partners 执行合伙人 Josh Wander 表示：“我们很高兴能够宣布我们与波音公司的订单规模几乎翻了一番。”“我们长期以来一直对737 MAX系列的经济性充满信心，但我们尤其对737-8-200机型感到兴奋，它占了我们新增订单的大部分。我们相信这款飞机将成为ULCC/LCC的标志性资产，尤其是在200以下座位市场。随着旅行需求的回归，777加速了我们在运营航空公司中追求运营成本和碳足迹效率。”在这些领域，737-8 非常引人注目，而 737-8-200 则是无与伦比的。”</blockquote></p><p> The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p><p><blockquote>与它所取代的飞机相比，737 MAX系列将燃油使用量和碳排放量减少了至少14%，从而降低了777合作伙伴附属航空公司的运营成本和环境足迹。每架737 MAX都配有令乘客满意的波音天空内饰，现代雕刻的侧壁和窗户展示、增强宽敞感的LED照明和更大的旋转头顶储物箱突出了这一点。</blockquote></p><p> \"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p><p><blockquote>波音公司商业销售和营销高级副总裁 Ihssane Mounir 表示：“我们非常感谢 777 合作伙伴对我们产品的信任，包括 737 MAX 的重复订单以及扩大机队以纳入大容量 737-8-200 机型。”“777 Partners 正在利用 737 系列的灵活性、可靠性和效率在未来几年为乘客提供服务，从而促进其附属低成本航空公司的增长。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>777 Partners Orders 30 Additional 737 MAX Airplanes<blockquote>777 合作伙伴订购 30 架额外 737 MAX 飞机</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n777 Partners Orders 30 Additional 737 MAX Airplanes<blockquote>777 合作伙伴订购 30 架额外 737 MAX 飞机</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-07 22:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p><p><blockquote>在收到 777 合作伙伴额外订购 30 架 737 MAX 喷气式飞机后，波音公司股价延续反弹势头。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Boeing&nbsp;and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p><p><blockquote>波音公司和 777 Partners 今天宣布，这家总部位于迈阿密的投资公司将通过额外购买 30 架喷气式飞机，将其 737 MAX 订单量增加近一倍。新订单将 777 Partners 的商用飞机产品组合扩大到总共 68 架 737 MAX，这是其今年第四次订购节能单通道喷气式飞机。该订单按标价计算价值 37 亿美元，将使 777 合作伙伴能够在其附属全球低成本航空公司的机队中扩大 737 MAX 业务。</blockquote></p><p> \"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p><p><blockquote>777 Partners 执行合伙人 Josh Wander 表示：“我们很高兴能够宣布我们与波音公司的订单规模几乎翻了一番。”“我们长期以来一直对737 MAX系列的经济性充满信心，但我们尤其对737-8-200机型感到兴奋，它占了我们新增订单的大部分。我们相信这款飞机将成为ULCC/LCC的标志性资产，尤其是在200以下座位市场。随着旅行需求的回归，777加速了我们在运营航空公司中追求运营成本和碳足迹效率。”在这些领域，737-8 非常引人注目，而 737-8-200 则是无与伦比的。”</blockquote></p><p> The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p><p><blockquote>与它所取代的飞机相比，737 MAX系列将燃油使用量和碳排放量减少了至少14%，从而降低了777合作伙伴附属航空公司的运营成本和环境足迹。每架737 MAX都配有令乘客满意的波音天空内饰，现代雕刻的侧壁和窗户展示、增强宽敞感的LED照明和更大的旋转头顶储物箱突出了这一点。</blockquote></p><p> \"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p><p><blockquote>波音公司商业销售和营销高级副总裁 Ihssane Mounir 表示：“我们非常感谢 777 合作伙伴对我们产品的信任，包括 737 MAX 的重复订单以及扩大机队以纳入大容量 737-8-200 机型。”“777 Partners 正在利用 737 系列的灵活性、可靠性和效率在未来几年为乘客提供服务，从而促进其附属低成本航空公司的增长。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107798974","content_text":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.\n\nBoeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.\n\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"\nThe 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.\n\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"","news_type":1,"symbols_score_info":{"BA":0.9}},"isVote":1,"tweetType":1,"viewCount":4249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606504688,"gmtCreate":1638890062281,"gmtModify":1638890088126,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606504688","repostId":"2189476639","repostType":4,"isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606898447,"gmtCreate":1638851130355,"gmtModify":1638851131288,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","listText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","text":"$Twitter(TWTR)$เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","images":[{"img":"https://static.tigerbbs.com/6da83692b0f892c9884037c615ca74bd","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606898447","isVote":1,"tweetType":1,"viewCount":1116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":606149768,"gmtCreate":1638846484378,"gmtModify":1638846486449,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606149768","repostId":"1186134052","repostType":4,"repost":{"id":"1186134052","kind":"news","pubTimestamp":1638843447,"share":"https://www.laohunote.com/m/news/1186134052?lang=zh_CN&edition=full","pubTime":"2021-12-07 10:17","market":"us","language":"en","title":"RIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147<blockquote>RIVN 价格预测：为什么一位分析师认为Rivian股票将触及 147 美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186134052","media":"InvestorPlace","summary":"Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed","content":"<p><div> Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week Rivian Automative(NASDAQ:RIVN) had a rough go. RIVN stock dropped by 12% over the course...</p><p><blockquote><div>如今，某电动汽车（EV）制造商的投资者松了一口气。事实上，上周Rivian汽车公司（纳斯达克股票代码：RIVN）经历了一段艰难的时期。RIVN 股价在整个过程中下跌了 12%……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147<blockquote>RIVN 价格预测：为什么一位分析师认为Rivian股票将触及 147 美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147<blockquote>RIVN 价格预测：为什么一位分析师认为Rivian股票将触及 147 美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-07 10:17</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week Rivian Automative(NASDAQ:RIVN) had a rough go. RIVN stock dropped by 12% over the course...</p><p><blockquote><div>如今，某电动汽车（EV）制造商的投资者松了一口气。事实上，上周Rivian汽车公司（纳斯达克股票代码：RIVN）经历了一段艰难的时期。RIVN 股价在整个过程中下跌了 12%……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186134052","content_text":"Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week Rivian Automative(NASDAQ:RIVN) had a rough go. RIVN stock dropped by 12% over the course of the week.\nHowever, things are turning around today as Morgan Stanley(NYSE:MS)initiated coverage on RIVN stock with an overweight rating and a $147 price target. This price target represents an upside of 34% from current prices. In response, shares of RIVN stock are trading higher by 4%.\nLet’s take a look at the details of this new price prediction.\nRIVN Price Prediction: Is Rivian “The One” to Challenge Tesla?\nMorgan Stanley analyst Adam Jonas led the initiation coverage on Rivian. However, it wasn’t necessarily the price target that attracted the most attention. It was Jonas’ comment on Rivian competitor Tesla(NASDAQ:TSLA) that surprised many investors:\n\n “Rivian’s compelling product, strong management, and deterministic access to capital are underpinned by a strategic relationship with AMZN to decarbonize the final mile. We see it as ‘the one’ that can challenge Tesla.”\n\nA direct comparison between the two EV makers seems far off for now. However, Rivian may have the one-up on Tesla in terms of delivery vans. Jonas calls Rivian’s delivery vans “the most capable/desirable product in the market for $80k.” While Tesla has yet to enter the delivery van market, its strength lies in selling EVs directly to consumers.\nOn that note, Rivian launched its highly anticipated R1T pickup truck this year after supply chain delays. Deliveries for the pickup truck have started, although many customers who preordered are reporting that they won’t receive their order until 2022. Prices start at $67,5o0 for the base R1T model.\nAccording to Tipranks, Adam Jonas has a 57% success rate and an average return of 14.5% during a one-year period. Jonas is a highly regarded analyst and ranks at 465 out of the 7,727 total analysts thatTiprankstracks.\nThe Bottom Line on Rivian\nRivian remains a speculative investment with high future expectations. While Rivian has reported $0 in revenue for the trailing-12-month (TTM) period, the EV maker boasts an impressive ally in Amazon(NASDAQ:AMZN). Amazon is Rivian’s largest customer and owns roughly 20% of the company. Furthermore, the e-commerce giant has a massive pre-order for 100,000 delivery vans that is set to be completed by 2025. Analyst Adam Jonas believes the pre-order figure will increase to 300,000.\nAs of now, valuation, scalability and execution by management remain the biggest concerns. Before making an investment, investors need to sit down and rationalize whether Rivian can make enough deliveries in the future to support its current sky-high market capitalization of $90 billion.","news_type":1,"symbols_score_info":{"RIVN":0.9}},"isVote":1,"tweetType":1,"viewCount":1217,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608710604,"gmtCreate":1638788963960,"gmtModify":1638788968330,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Downstairs&nbsp;","listText":"Downstairs&nbsp;","text":"Downstairs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608710604","repostId":"2138143109","repostType":4,"isVote":1,"tweetType":1,"viewCount":1475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601790846,"gmtCreate":1638556737583,"gmtModify":1638556738033,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"😢","listText":"😢","text":"😢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601790846","repostId":"1195177271","repostType":4,"repost":{"id":"1195177271","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638542957,"share":"https://www.laohunote.com/m/news/1195177271?lang=zh_CN&edition=full","pubTime":"2021-12-03 22:49","market":"us","language":"en","title":"Hot chinese concept stocks dipped in morning trading<blockquote>热门中国概念股早盘下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195177271","media":"Tiger Newspress","summary":"Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.","content":"<p>Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.</p><p><blockquote>热门中国概念股早盘下跌。阿里巴巴、京东、拼多多、百度、网易、哔哩哔哩、蔚来、小鹏汽车、理想汽车、滴滴全球和科控股跌幅在4%至10%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/364eb167dd032a1d1046b0f329d247db\" tg-width=\"402\" tg-height=\"666\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot chinese concept stocks dipped in morning trading<blockquote>热门中国概念股早盘下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot chinese concept stocks dipped in morning trading<blockquote>热门中国概念股早盘下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-03 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.</p><p><blockquote>热门中国概念股早盘下跌。阿里巴巴、京东、拼多多、百度、网易、哔哩哔哩、蔚来、小鹏汽车、理想汽车、滴滴全球和科控股跌幅在4%至10%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/364eb167dd032a1d1046b0f329d247db\" tg-width=\"402\" tg-height=\"666\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTES":"网易","XPEV":"小鹏集团","PDD":"拼多多","BEKE":"贝壳","BIDU":"百度","BILI":"哔哩哔哩","JD":"京东","LI":"理想汽车","NIO":"蔚来","BABA":"阿里巴巴","DIDI":"滴滴(已退市)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195177271","content_text":"Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.","news_type":1,"symbols_score_info":{"BEKE":0.9,"BABA":0.9,"NTES":0.9,"BIDU":0.9,"DIDI":0.9,"NIO":0.9,"BILI":0.9,"JD":0.9,"PDD":0.9,"XPEV":0.9,"LI":0.9}},"isVote":1,"tweetType":1,"viewCount":1251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601210045,"gmtCreate":1638533688808,"gmtModify":1638533703139,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601210045","repostId":"1144924535","repostType":4,"repost":{"id":"1144924535","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638533072,"share":"https://www.laohunote.com/m/news/1144924535?lang=zh_CN&edition=full","pubTime":"2021-12-03 20:04","market":"us","language":"en","title":"Moderna stock jumped more than 5% in premarket trading<blockquote>Moderna 股价在盘前交易中上涨超过 5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144924535","media":"老虎资讯综合","summary":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in","content":"<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p><p><blockquote>Moderna 股票在盘前交易中上涨超过 5%，因为 Moderna 在英国 COVID-19 加强试验中的抗体反应领先..</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p><p><blockquote>根据发表在<i>柳叶刀</i>周四，Moderna新冠肺炎疫苗在一项评估新冠肺炎疫苗作为加强剂的不同组合的试验中显示出最强的抗体效果。</blockquote></p><p> The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p><p><blockquote>在英国18个不同地点进行的第二阶段“COV-Boost”研究涉及近2900名30岁以上的人。研究中一半的人接种了两剂牛津-阿斯利康疫苗，其余的人接种了辉瑞/BioNTec疫苗。</blockquote></p><p> The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p><p><blockquote>该试验旨在评估阿斯利康、辉瑞/BioNTech、Novavax、强生、Moderna、Valneva和Curevac开发的七种加强疫苗的安全性和有效性。</blockquote></p><p> While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p><p><blockquote>虽然除 Valneva (VALN) 疫苗外，所有七种疫苗都能增强最初接种辉瑞/ BioNTech 疫苗的人的免疫力，但在阿斯利康疫苗初始治疗方案 10-12 周后接种时，所有七种疫苗都能提高免疫水平。</blockquote></p><p> Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p><p><blockquote>值得注意的是，Moderna COVID-19注射产生了最强的加强效应，导致阿斯利康组的抗体水平上升超过32倍，辉瑞/BioNTech组的抗体水平上升超过11倍，<i>卫报</i>报道。</blockquote></p><p> In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p><p><blockquote>此外，英国周三表示，已同意再购买 1.14 亿支辉瑞/BioNTech 和 Moderna COVID-19 疫苗，并表示鉴于新奥密克戎变种的出现，英国已加快签署新合同。</blockquote></p><p> The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p><p><blockquote>英国卫生部表示，该协议涉及明年和 2023 年额外提供 6000 万剂 Moderna 疫苗和 5400 万剂辉瑞疫苗，如果需要对抗奥密克戎毒株或任何其他变种，还将包括获得任何改良疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped more than 5% in premarket trading<blockquote>Moderna 股价在盘前交易中上涨超过 5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped more than 5% in premarket trading<blockquote>Moderna 股价在盘前交易中上涨超过 5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-12-03 20:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p><p><blockquote>Moderna 股票在盘前交易中上涨超过 5%，因为 Moderna 在英国 COVID-19 加强试验中的抗体反应领先..</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p><p><blockquote>根据发表在<i>柳叶刀</i>周四，Moderna新冠肺炎疫苗在一项评估新冠肺炎疫苗作为加强剂的不同组合的试验中显示出最强的抗体效果。</blockquote></p><p> The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p><p><blockquote>在英国18个不同地点进行的第二阶段“COV-Boost”研究涉及近2900名30岁以上的人。研究中一半的人接种了两剂牛津-阿斯利康疫苗，其余的人接种了辉瑞/BioNTec疫苗。</blockquote></p><p> The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p><p><blockquote>该试验旨在评估阿斯利康、辉瑞/BioNTech、Novavax、强生、Moderna、Valneva和Curevac开发的七种加强疫苗的安全性和有效性。</blockquote></p><p> While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p><p><blockquote>虽然除 Valneva (VALN) 疫苗外，所有七种疫苗都能增强最初接种辉瑞/ BioNTech 疫苗的人的免疫力，但在阿斯利康疫苗初始治疗方案 10-12 周后接种时，所有七种疫苗都能提高免疫水平。</blockquote></p><p> Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p><p><blockquote>值得注意的是，Moderna COVID-19注射产生了最强的加强效应，导致阿斯利康组的抗体水平上升超过32倍，辉瑞/BioNTech组的抗体水平上升超过11倍，<i>卫报</i>报道。</blockquote></p><p> In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p><p><blockquote>此外，英国周三表示，已同意再购买 1.14 亿支辉瑞/BioNTech 和 Moderna COVID-19 疫苗，并表示鉴于新奥密克戎变种的出现，英国已加快签署新合同。</blockquote></p><p> The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p><p><blockquote>英国卫生部表示，该协议涉及明年和 2023 年额外提供 6000 万剂 Moderna 疫苗和 5400 万剂辉瑞疫苗，如果需要对抗奥密克戎毒株或任何其他变种，还将包括获得任何改良疫苗。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144924535","content_text":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..\n\nAccording to a peer-reviewed study published in The Lancet on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.\nThe Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.\nThe trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.\nWhile all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.\nNotably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, The Guardian reported.\nIn addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.\nThe deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603553063,"gmtCreate":1638431137685,"gmtModify":1638431139320,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603553063","repostId":"1197973971","repostType":4,"repost":{"id":"1197973971","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638429281,"share":"https://www.laohunote.com/m/news/1197973971?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:14","market":"us","language":"en","title":"Glaxo says its vaccine retains activity against key Omicron mutations<blockquote>葛兰素史克称其疫苗保留针对关键奥密克戎突变的活性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973971","media":"Tiger Newspress","summary":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint ser","content":"<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p><p><blockquote>葛兰素史克公司和Vir Biotechnology，Inc.今天宣布对预印本服务器bioRxiv进行更新，临床前数据表明，在研单克隆抗体sotrovimab保留了对新的奥密克戎新型冠状病毒变体（B.1.1.529）的关键突变[1]的活性，包括在sotrovimab的结合位点发现的突变。这些数据是通过对在奥密克戎发现的特定个体突变进行假病毒测试产生的。迄今为止，sotrovimab已显示出针对世界卫生组织（WHO）定义的所有受关注和关注的检测变异株的持续活性。两家公司目前正在完成体外假病毒测试，以确认sotrovimab针对所有奥密克戎突变组合的中和活性，并打算在2021年底前提供更新。</blockquote></p><p> <b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p><p><blockquote><b>Vir 首席执行官 George Scangos 博士表示：</b>“Sotrovimab 在设计时就考虑到了一种变异病毒。通过靶向刺突蛋白中一个高度保守、不太可能发生变异的区域，我们希望既能解决当前的 SARS-CoV-2 病毒，也能解决我们预计不可避免的未来变异。这一假设已被一次又一次地证实--临床前数据证明，它能够持续保持对迄今为止所有令人担忧和感兴趣的测试变异株的活性，包括在奥密克戎发现的关键变异株。我们完全期待这种积极的趋势将继续下去，并正在迅速努力确认它对奥密克戎的完整组合序列的影响。”</blockquote></p><p> <b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p><p><blockquote><b>葛兰素史克首席科学官兼研发总裁 Hal Barron 博士表示：</b>“自大流行开始以来，我们一直与 Vir 合作，将我们的科学专业知识和技术相结合，为 COVID-19 患者提供一种持久的治疗方案。虽然还为时尚早，但这些临床前数据支持了我们长期以来的观点，即随着病毒的不断变异，sotrovimab 仍有潜力保持其活性。我们很高兴美国和许多其他国家的患者可以使用这种治疗方案，并正在努力在全球范围内扩大使用范围。”</blockquote></p><p> <b>About sotrovimab</b></p><p><blockquote><b>关于sotrovimab</b></blockquote></p><p> Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p><p><blockquote>Sotrovimab是一种在研新型冠状病毒中和单克隆抗体。该抗体与SARS-CoV-1（引起SARS的病毒）共有的SARS-CoV-2上的表位结合，表明该表位高度保守，这可能会使耐药性更难发展。Sotrovimab，结合了Xencor的Xtend™该技术还旨在实现肺部的高浓度，以确保最佳渗透到受新型冠状病毒影响的气道组织中，并延长半衰期。</blockquote></p><p> Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p><p><blockquote>发表在bioRxiv上的更新体外数据表明，sotrovimab对世卫组织定义的所有当前检测的新型冠状病毒病毒（SARS-CoV-2病毒）以及其他变体（包括但不限于Delta（B.1.617.2）、Delta Plus（AY.1或AY.2）、Mu（B.1.621）和奥密克戎病毒（B.1.1.529）的关键突变保留活性。</blockquote></p><p> <b>About the sotrovimab clinical development programme</b></p><p><blockquote><b>关于sotrovimab临床开发计划</b></blockquote></p><p></p><p> <ul>  <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>  <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>  <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>  <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li> </ul> <b>About global access to sotrovimab</b></p><p><blockquote><ul><li>COMET-ICE：一项III期、多中心、双盲、安慰剂对照试验调查了在患有轻度至中度新冠肺炎且有发展为严重疾病高风险、未住院且不需要氧气的成人中静脉（IV）输注sotrovimab。在1,057名参与者的完整试验人群中的最终COMET-ICE试验结果显示，与安慰剂相比，到第29天，住院超过24小时或因任何原因导致的死亡减少了79%（调整后的相对风险减少）（p&lt;0.001），达到了试验的主要终点。中期数据于<i>新英格兰医学杂志</i>于二零二一年十月二十七日公布，最终数据于二零二一年十一月八日预先公布。<i>medRxiv</i>.</li><li>COMET-TAIL：一项III期、随机、多中心、开放标签、非劣效性试验，研究肌肉注射（IM）与静脉注射sotrovimab用于高风险非住院成人和儿科患者（12岁及以上）的轻中度新冠肺炎的早期治疗。该试验的主要终点达到了，头条数据表明，肌肉注射索特罗维单抗的疗效非劣效，对高危人群的疗效与静脉注射相似。两家公司计划将完整的彗尾数据提交给同行评审期刊，以便在2022年第一季度发表。</li><li>COMET-PEAK：一项II期、随机、多中心、平行组试验，评估轻中度新冠肺炎门诊患者静脉注射和肌肉注射sotrovimab。迄今为止，来自试验开放标签B部分（500mg IV vs 500mg IM）的数据证明了IM组和IV组之间病毒学应答的等效性。两家公司计划将完整的彗星峰数据集提交给同行评审期刊，以便在适当的时候发表。</li><li>葛兰素史克和Vir还在合作研究sotrovimab在未感染的免疫功能低下成人中的使用，以确定sotrovimab是否可以预防有症状的新冠肺炎感染。葛兰素史克和Vir正在支持研究者赞助的研究，并促进与参与免疫功能低下患者连续护理的经验丰富的研究者和网络的科学合作，以了解sotrovimab在该人群中的预防作用。将在适当时候与监管机构讨论预防计划。</li></ul><b>关于sotrovimab的全球准入</b></blockquote></p><p> <ul>  <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>  <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>  <li>COVID-19.</li>  <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li> </ul> <b>Sotrovimab in the United States</b></p><p><blockquote><ul><li>Sotrovimab在美国被授权用于紧急使用。根据欧盟人用药品委员会（CHMP）第726/2004号法规第5（3）条，Xevudy（sotrovimab）获得了积极的科学意见，在澳大利亚获得了临时上市许可，在沙特阿拉伯获得了有条件上市许可。在日本，它已通过紧急途径特别批准获得批准。sotrovimab 已在十几个国家获得临时授权。</li><li>葛兰素史克和Vir最近还向欧洲药品管理局提交了Xevudy（sotrovimab）的营销授权申请（MAA），用于治疗患有2019冠状病毒病（COVID-19）的成人和青少年（12岁及以上，体重至少40公斤），他们不需要补充氧气，并且有进展为重症的风险</li><li>新冠肺炎。</li><li>Sotrovimab在全球多个国家供应，包括通过美国、英国、日本、澳大利亚、加拿大、新加坡、瑞士和阿拉伯联合酋长国的国家协议供应。我们还与欧盟委员会签署了一份联合采购协议，以供应sotrovimab的剂量。由于保密或监管要求，其他协议尚未公布。</li></ul><b>美国的Sotrovimab</b></blockquote></p><p> The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p><p><blockquote>以下是sotrovimab的信息总结。美国的医疗保健提供者应查看情况说明书，了解有关sotrovimab授权使用和EUA强制性要求的信息。请参阅美国食品药品监督管理局（FDA）授权书、医疗保健提供者的完整情况说明书以及患者、父母和护理人员的完整情况说明书。</blockquote></p><p> Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p><p><blockquote>Sotrovimab已被美国FDA授权用于下述紧急用途。Sotrovimab未获得FDA批准用于此用途。</blockquote></p><p> Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p><p><blockquote>根据《法案》第564（b）（1）节，21 U.S.C.§360bbb-3（b）（1），索特罗维单抗仅在声明存在证明索特罗维单抗紧急使用授权的情况期间获得授权，除非授权提前终止或撤销。</blockquote></p><p> <b>Authorized Use</b></p><p><blockquote><b>授权使用</b></blockquote></p><p></p><p> The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p><p><blockquote>美国FDA已发布紧急使用授权（EUA），允许紧急使用未经批准的产品sotrovimab治疗轻度至中度冠状病毒疾病2019（COVID-19），用于直接SARS-CoV-2病毒检测结果呈阳性的成人和儿童患者（12岁及以上，体重至少40公斤），以及进展为重度COVID-19的高风险患者，包括住院或死亡。</blockquote></p><p> <b>Limitations of Authorized Use</b></p><p><blockquote><b>授权使用的限制</b></blockquote></p><p> Sotrovimab is not authorized for use in patients:</p><p><blockquote>Sotrovimab未被批准用于以下患者：</blockquote></p><p> <ul>  <li>who are hospitalized due to COVID-19, OR</li>  <li>who require oxygen therapy due to COVID-19, OR</li>  <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li> </ul> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p><p><blockquote><ul><li>因新冠肺炎住院的人，或</li><li>因新冠肺炎需要氧疗的人，或</li><li>由于新冠肺炎需要增加基线氧流速的患者（由于潜在的非新冠肺炎相关合并症而接受慢性氧疗的患者）</li></ul>在因新冠肺炎住院的患者中，尚未观察到sotrovimab治疗的获益。当对需要高流量氧气或机械通气的COVID-19住院患者施用新型冠状病毒单克隆抗体时，可能会导致更差的临床结果。</blockquote></p><p> <b>Important Safety Information</b></p><p><blockquote><b>重要安全信息</b></blockquote></p><p> <b>CONTRAINDICATIONS</b></p><p><blockquote><b>禁忌症</b></blockquote></p><p> Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p><p><blockquote>对索特罗维单抗或制剂中的任何赋形剂有过敏反应史的患者禁用索特罗维单抗。</blockquote></p><p> <b>WARNINGS AND PRECAUTIONS</b></p><p><blockquote><b>警告和注意事项</b></blockquote></p><p> There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p><p><blockquote>sotrovimab的临床数据有限。使用sotrovimab可能会发生以前未报告的严重和意外不良事件。</blockquote></p><p> <b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p><p><blockquote><b>过敏反应，包括过敏反应和输液相关反应</b></blockquote></p><p> Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p><p><blockquote>使用sotrovimab时观察到严重的过敏反应，包括过敏反应。如果出现具有临床意义的超敏反应或过敏反应的体征和症状，应立即停止给药并开始适当的药物治疗和/或支持性护理。</blockquote></p><p> Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p><p><blockquote>在施用sotrovimab时，观察到输注期间和输注后24小时内发生的输注相关反应。这些反应可能是严重的或危及生命的。</blockquote></p><p> Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p><p><blockquote>输注相关反应的体征和症状可能包括：发热、呼吸困难、氧饱和度降低、寒战、疲劳、心律失常（例如，房颤、窦性心动过速、心动过缓）、胸痛或不适、虚弱、精神状态改变、恶心、头痛、支气管痉挛、低血压、高血压、血管性水肿、咽喉刺激、皮疹（包括荨麻疹）、瘙痒、肌痛、血管迷走神经反应（例如，晕厥前、晕厥）、头晕和出汗。</blockquote></p><p> Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p><p><blockquote>如果发生输注相关反应，考虑减慢或停止输注，并给予适当的药物和/或支持性护理。</blockquote></p><p> Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p><p><blockquote>在紧急使用授权下使用新型冠状病毒单克隆抗体时，也有在输注后超过24小时发生的超敏反应的报道。</blockquote></p><p> <b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p><p><blockquote><b>SARS-CoV-2单克隆抗体给药后临床恶化</b></blockquote></p><p> Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p><p><blockquote>据报道，在给予新型冠状病毒单克隆抗体治疗后，COVID-19的临床恶化，可能包括发热、缺氧或呼吸困难增加、心律失常（如心房颤动、心动过速、心动过缓）、疲劳和精神状态改变的体征或症状。其中一些事件需要住院治疗。尚不清楚这些事件是与新型冠状病毒单克隆抗体的使用有关，还是由于COVID-19的进展。</blockquote></p><p> <b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p><p><blockquote><b>重症COVID-19患者的获益局限性和潜在风险</b></blockquote></p><p> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p><p><blockquote>在因新冠肺炎住院的患者中，尚未观察到sotrovimab治疗的获益。当对需要高流量氧气或机械通气的COVID-19住院患者施用新型冠状病毒单克隆抗体时，可能会导致更差的临床结果。因此，sotrovimab未被授权用于以下患者：因COVID-19住院的患者，或因COVID-19需要氧疗的患者，或因潜在的非COVID-19相关合并症而需要增加基线氧流速的患者。</blockquote></p><p> <b>ADVERSE EVENTS</b></p><p><blockquote><b>不良事件</b></blockquote></p><p> Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p><p><blockquote>在COMET-ICE中，接受sotrovimab治疗的患者中有2%观察到过敏反应，接受安慰剂治疗的患者中有1%观察到过敏反应。</blockquote></p><p> The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p><p><blockquote>在COMET-ICE中，sotrovimab治疗组中观察到的最常见的治疗后出现的不良事件是皮疹（1%）和腹泻（2%），均为1级（轻度）或2级（中度）。与安慰剂相比，sotrovimab组未报告其他治疗中出现的不良事件发生率更高。</blockquote></p><p> <b>USE IN SPECIFIC POPULATIONS</b></p><p><blockquote><b>在特定人群中使用</b></blockquote></p><p> <b>Pregnancy</b></p><p><blockquote><b>妊娠</b></blockquote></p><p></p><p> There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p><p><blockquote>没有足够的数据来评估主要出生缺陷、流产或不良母体或胎儿结局的药物相关风险。只有在潜在获益证明对母亲和胎儿的潜在风险合理的情况下，才应在妊娠期间使用Sotrovimab。</blockquote></p><p> <b>Lactation</b></p><p><blockquote><b>哺乳期</b></blockquote></p><p> There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p><p><blockquote>目前尚无关于索曲维单抗在母乳中的存在、对母乳喂养婴儿的影响或对乳汁分泌的影响的数据。正在母乳喂养的新冠肺炎患者应遵循临床指南的做法，以避免婴儿接触新冠肺炎。</blockquote></p><p> <b>About the GSK and Vir collaboration</b></p><p><blockquote><b>关于葛兰素史克与 Vir 的合作</b></blockquote></p><p> In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p><p><blockquote>2020 年 4 月，葛兰素史克和 Vir 合作研究和开发冠状病毒解决方案，包括导致 COVID-19 的 SARS-CoV-2 病毒。此次合作利用 Vir 专有的单克隆抗体平台技术来加速现有的抗病毒抗体，并确定新的抗病毒抗体，这些抗体可用作治疗或预防方案，以帮助应对当前的 COVID-19 大流行和未来的疫情。两家公司将利用葛兰素史克在功能基因组学方面的专业知识，结合其在 CRISPR 筛选和人工智能方面的能力，以识别针对细胞宿主基因的抗冠状病毒化合物。他们还将运用他们的综合专业知识来研究新型冠状病毒和其他冠状病毒疫苗。</blockquote></p><p> <b>GSK commitment to tackling COVID-19</b></p><p><blockquote><b>葛兰素史克致力于应对 COVID-19</b></blockquote></p><p> GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p><p><blockquote>葛兰素史克对 COVID-19 的回应是业内最广泛的回应之一，除了我们与合作伙伴机构开发的候选疫苗外，还有潜在的治疗方法。</blockquote></p><p> GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p><p><blockquote>葛兰素史克正在通过提供我们的佐剂技术，与多个组织合作研发新冠肺炎疫苗。我们正在与Sanofi S.A.、Medicago Inc.和SK bioscience Co., Ltd.合作开发佐剂、基于蛋白质的候选疫苗，目前所有疫苗都处于III期临床试验阶段。佐剂的使用在疫情中可能特别重要，因为它可以减少每剂所需的疫苗蛋白量，允许生产更多疫苗剂量，并有助于保护更多有需要的人。</blockquote></p><p> GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p><p><blockquote>葛兰素史克还与mRNA专家CureVac N.V.合作，共同开发针对新冠肺炎的下一代优化mRNA疫苗，有可能在一种疫苗中解决多种新兴变异。</blockquote></p><p> GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p><p><blockquote>葛兰素史克还在探索针对 COVID-19 患者的治疗方法，与 Vir Biotechnology 合作研究可用作 COVID-19 治疗或预防选择的单克隆抗体。</blockquote></p><p> <b>Vir’s commitment to COVID-19</b></p><p><blockquote><b>Vir对COVID-19的承诺</b></blockquote></p><p> Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p><p><blockquote>Vir 的成立宗旨是解决世界上最严重的传染病问题。2020 年，Vir 利用我们独特的科学见解和行业领先的抗体平台，探索多种单克隆抗体作为 COVID-19 的潜在治疗或预防选择，迅速应对 COVID-19 疫情。Sotrovimab是第一个推进到临床的SARS-CoV-2靶向抗体Vir。它是经过精心挑选的，因为它在临床前研究中证明的前景，包括预期的高耐药屏障和阻止病毒进入健康细胞和清除受感染细胞的潜在能力。Vir将继续寻求新的治疗和预防解决方案，以对抗新型冠状病毒和未来的冠状病毒大流行，无论是独立还是与其合作伙伴合作。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo says its vaccine retains activity against key Omicron mutations<blockquote>葛兰素史克称其疫苗保留针对关键奥密克戎突变的活性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo says its vaccine retains activity against key Omicron mutations<blockquote>葛兰素史克称其疫苗保留针对关键奥密克戎突变的活性</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 15:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p><p><blockquote>葛兰素史克公司和Vir Biotechnology，Inc.今天宣布对预印本服务器bioRxiv进行更新，临床前数据表明，在研单克隆抗体sotrovimab保留了对新的奥密克戎新型冠状病毒变体（B.1.1.529）的关键突变[1]的活性，包括在sotrovimab的结合位点发现的突变。这些数据是通过对在奥密克戎发现的特定个体突变进行假病毒测试产生的。迄今为止，sotrovimab已显示出针对世界卫生组织（WHO）定义的所有受关注和关注的检测变异株的持续活性。两家公司目前正在完成体外假病毒测试，以确认sotrovimab针对所有奥密克戎突变组合的中和活性，并打算在2021年底前提供更新。</blockquote></p><p> <b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p><p><blockquote><b>Vir 首席执行官 George Scangos 博士表示：</b>“Sotrovimab 在设计时就考虑到了一种变异病毒。通过靶向刺突蛋白中一个高度保守、不太可能发生变异的区域，我们希望既能解决当前的 SARS-CoV-2 病毒，也能解决我们预计不可避免的未来变异。这一假设已被一次又一次地证实--临床前数据证明，它能够持续保持对迄今为止所有令人担忧和感兴趣的测试变异株的活性，包括在奥密克戎发现的关键变异株。我们完全期待这种积极的趋势将继续下去，并正在迅速努力确认它对奥密克戎的完整组合序列的影响。”</blockquote></p><p> <b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p><p><blockquote><b>葛兰素史克首席科学官兼研发总裁 Hal Barron 博士表示：</b>“自大流行开始以来，我们一直与 Vir 合作，将我们的科学专业知识和技术相结合，为 COVID-19 患者提供一种持久的治疗方案。虽然还为时尚早，但这些临床前数据支持了我们长期以来的观点，即随着病毒的不断变异，sotrovimab 仍有潜力保持其活性。我们很高兴美国和许多其他国家的患者可以使用这种治疗方案，并正在努力在全球范围内扩大使用范围。”</blockquote></p><p> <b>About sotrovimab</b></p><p><blockquote><b>关于sotrovimab</b></blockquote></p><p> Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p><p><blockquote>Sotrovimab是一种在研新型冠状病毒中和单克隆抗体。该抗体与SARS-CoV-1（引起SARS的病毒）共有的SARS-CoV-2上的表位结合，表明该表位高度保守，这可能会使耐药性更难发展。Sotrovimab，结合了Xencor的Xtend™该技术还旨在实现肺部的高浓度，以确保最佳渗透到受新型冠状病毒影响的气道组织中，并延长半衰期。</blockquote></p><p> Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p><p><blockquote>发表在bioRxiv上的更新体外数据表明，sotrovimab对世卫组织定义的所有当前检测的新型冠状病毒病毒（SARS-CoV-2病毒）以及其他变体（包括但不限于Delta（B.1.617.2）、Delta Plus（AY.1或AY.2）、Mu（B.1.621）和奥密克戎病毒（B.1.1.529）的关键突变保留活性。</blockquote></p><p> <b>About the sotrovimab clinical development programme</b></p><p><blockquote><b>关于sotrovimab临床开发计划</b></blockquote></p><p></p><p> <ul>  <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>  <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>  <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>  <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li> </ul> <b>About global access to sotrovimab</b></p><p><blockquote><ul><li>COMET-ICE：一项III期、多中心、双盲、安慰剂对照试验调查了在患有轻度至中度新冠肺炎且有发展为严重疾病高风险、未住院且不需要氧气的成人中静脉（IV）输注sotrovimab。在1,057名参与者的完整试验人群中的最终COMET-ICE试验结果显示，与安慰剂相比，到第29天，住院超过24小时或因任何原因导致的死亡减少了79%（调整后的相对风险减少）（p&lt;0.001），达到了试验的主要终点。中期数据于<i>新英格兰医学杂志</i>于二零二一年十月二十七日公布，最终数据于二零二一年十一月八日预先公布。<i>medRxiv</i>.</li><li>COMET-TAIL：一项III期、随机、多中心、开放标签、非劣效性试验，研究肌肉注射（IM）与静脉注射sotrovimab用于高风险非住院成人和儿科患者（12岁及以上）的轻中度新冠肺炎的早期治疗。该试验的主要终点达到了，头条数据表明，肌肉注射索特罗维单抗的疗效非劣效，对高危人群的疗效与静脉注射相似。两家公司计划将完整的彗尾数据提交给同行评审期刊，以便在2022年第一季度发表。</li><li>COMET-PEAK：一项II期、随机、多中心、平行组试验，评估轻中度新冠肺炎门诊患者静脉注射和肌肉注射sotrovimab。迄今为止，来自试验开放标签B部分（500mg IV vs 500mg IM）的数据证明了IM组和IV组之间病毒学应答的等效性。两家公司计划将完整的彗星峰数据集提交给同行评审期刊，以便在适当的时候发表。</li><li>葛兰素史克和Vir还在合作研究sotrovimab在未感染的免疫功能低下成人中的使用，以确定sotrovimab是否可以预防有症状的新冠肺炎感染。葛兰素史克和Vir正在支持研究者赞助的研究，并促进与参与免疫功能低下患者连续护理的经验丰富的研究者和网络的科学合作，以了解sotrovimab在该人群中的预防作用。将在适当时候与监管机构讨论预防计划。</li></ul><b>关于sotrovimab的全球准入</b></blockquote></p><p> <ul>  <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>  <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>  <li>COVID-19.</li>  <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li> </ul> <b>Sotrovimab in the United States</b></p><p><blockquote><ul><li>Sotrovimab在美国被授权用于紧急使用。根据欧盟人用药品委员会（CHMP）第726/2004号法规第5（3）条，Xevudy（sotrovimab）获得了积极的科学意见，在澳大利亚获得了临时上市许可，在沙特阿拉伯获得了有条件上市许可。在日本，它已通过紧急途径特别批准获得批准。sotrovimab 已在十几个国家获得临时授权。</li><li>葛兰素史克和Vir最近还向欧洲药品管理局提交了Xevudy（sotrovimab）的营销授权申请（MAA），用于治疗患有2019冠状病毒病（COVID-19）的成人和青少年（12岁及以上，体重至少40公斤），他们不需要补充氧气，并且有进展为重症的风险</li><li>新冠肺炎。</li><li>Sotrovimab在全球多个国家供应，包括通过美国、英国、日本、澳大利亚、加拿大、新加坡、瑞士和阿拉伯联合酋长国的国家协议供应。我们还与欧盟委员会签署了一份联合采购协议，以供应sotrovimab的剂量。由于保密或监管要求，其他协议尚未公布。</li></ul><b>美国的Sotrovimab</b></blockquote></p><p> The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p><p><blockquote>以下是sotrovimab的信息总结。美国的医疗保健提供者应查看情况说明书，了解有关sotrovimab授权使用和EUA强制性要求的信息。请参阅美国食品药品监督管理局（FDA）授权书、医疗保健提供者的完整情况说明书以及患者、父母和护理人员的完整情况说明书。</blockquote></p><p> Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p><p><blockquote>Sotrovimab已被美国FDA授权用于下述紧急用途。Sotrovimab未获得FDA批准用于此用途。</blockquote></p><p> Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p><p><blockquote>根据《法案》第564（b）（1）节，21 U.S.C.§360bbb-3（b）（1），索特罗维单抗仅在声明存在证明索特罗维单抗紧急使用授权的情况期间获得授权，除非授权提前终止或撤销。</blockquote></p><p> <b>Authorized Use</b></p><p><blockquote><b>授权使用</b></blockquote></p><p></p><p> The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p><p><blockquote>美国FDA已发布紧急使用授权（EUA），允许紧急使用未经批准的产品sotrovimab治疗轻度至中度冠状病毒疾病2019（COVID-19），用于直接SARS-CoV-2病毒检测结果呈阳性的成人和儿童患者（12岁及以上，体重至少40公斤），以及进展为重度COVID-19的高风险患者，包括住院或死亡。</blockquote></p><p> <b>Limitations of Authorized Use</b></p><p><blockquote><b>授权使用的限制</b></blockquote></p><p> Sotrovimab is not authorized for use in patients:</p><p><blockquote>Sotrovimab未被批准用于以下患者：</blockquote></p><p> <ul>  <li>who are hospitalized due to COVID-19, OR</li>  <li>who require oxygen therapy due to COVID-19, OR</li>  <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li> </ul> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p><p><blockquote><ul><li>因新冠肺炎住院的人，或</li><li>因新冠肺炎需要氧疗的人，或</li><li>由于新冠肺炎需要增加基线氧流速的患者（由于潜在的非新冠肺炎相关合并症而接受慢性氧疗的患者）</li></ul>在因新冠肺炎住院的患者中，尚未观察到sotrovimab治疗的获益。当对需要高流量氧气或机械通气的COVID-19住院患者施用新型冠状病毒单克隆抗体时，可能会导致更差的临床结果。</blockquote></p><p> <b>Important Safety Information</b></p><p><blockquote><b>重要安全信息</b></blockquote></p><p> <b>CONTRAINDICATIONS</b></p><p><blockquote><b>禁忌症</b></blockquote></p><p> Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p><p><blockquote>对索特罗维单抗或制剂中的任何赋形剂有过敏反应史的患者禁用索特罗维单抗。</blockquote></p><p> <b>WARNINGS AND PRECAUTIONS</b></p><p><blockquote><b>警告和注意事项</b></blockquote></p><p> There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p><p><blockquote>sotrovimab的临床数据有限。使用sotrovimab可能会发生以前未报告的严重和意外不良事件。</blockquote></p><p> <b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p><p><blockquote><b>过敏反应，包括过敏反应和输液相关反应</b></blockquote></p><p> Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p><p><blockquote>使用sotrovimab时观察到严重的过敏反应，包括过敏反应。如果出现具有临床意义的超敏反应或过敏反应的体征和症状，应立即停止给药并开始适当的药物治疗和/或支持性护理。</blockquote></p><p> Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p><p><blockquote>在施用sotrovimab时，观察到输注期间和输注后24小时内发生的输注相关反应。这些反应可能是严重的或危及生命的。</blockquote></p><p> Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p><p><blockquote>输注相关反应的体征和症状可能包括：发热、呼吸困难、氧饱和度降低、寒战、疲劳、心律失常（例如，房颤、窦性心动过速、心动过缓）、胸痛或不适、虚弱、精神状态改变、恶心、头痛、支气管痉挛、低血压、高血压、血管性水肿、咽喉刺激、皮疹（包括荨麻疹）、瘙痒、肌痛、血管迷走神经反应（例如，晕厥前、晕厥）、头晕和出汗。</blockquote></p><p> Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p><p><blockquote>如果发生输注相关反应，考虑减慢或停止输注，并给予适当的药物和/或支持性护理。</blockquote></p><p> Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p><p><blockquote>在紧急使用授权下使用新型冠状病毒单克隆抗体时，也有在输注后超过24小时发生的超敏反应的报道。</blockquote></p><p> <b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p><p><blockquote><b>SARS-CoV-2单克隆抗体给药后临床恶化</b></blockquote></p><p> Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p><p><blockquote>据报道，在给予新型冠状病毒单克隆抗体治疗后，COVID-19的临床恶化，可能包括发热、缺氧或呼吸困难增加、心律失常（如心房颤动、心动过速、心动过缓）、疲劳和精神状态改变的体征或症状。其中一些事件需要住院治疗。尚不清楚这些事件是与新型冠状病毒单克隆抗体的使用有关，还是由于COVID-19的进展。</blockquote></p><p> <b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p><p><blockquote><b>重症COVID-19患者的获益局限性和潜在风险</b></blockquote></p><p> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p><p><blockquote>在因新冠肺炎住院的患者中，尚未观察到sotrovimab治疗的获益。当对需要高流量氧气或机械通气的COVID-19住院患者施用新型冠状病毒单克隆抗体时，可能会导致更差的临床结果。因此，sotrovimab未被授权用于以下患者：因COVID-19住院的患者，或因COVID-19需要氧疗的患者，或因潜在的非COVID-19相关合并症而需要增加基线氧流速的患者。</blockquote></p><p> <b>ADVERSE EVENTS</b></p><p><blockquote><b>不良事件</b></blockquote></p><p> Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p><p><blockquote>在COMET-ICE中，接受sotrovimab治疗的患者中有2%观察到过敏反应，接受安慰剂治疗的患者中有1%观察到过敏反应。</blockquote></p><p> The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p><p><blockquote>在COMET-ICE中，sotrovimab治疗组中观察到的最常见的治疗后出现的不良事件是皮疹（1%）和腹泻（2%），均为1级（轻度）或2级（中度）。与安慰剂相比，sotrovimab组未报告其他治疗中出现的不良事件发生率更高。</blockquote></p><p> <b>USE IN SPECIFIC POPULATIONS</b></p><p><blockquote><b>在特定人群中使用</b></blockquote></p><p> <b>Pregnancy</b></p><p><blockquote><b>妊娠</b></blockquote></p><p></p><p> There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p><p><blockquote>没有足够的数据来评估主要出生缺陷、流产或不良母体或胎儿结局的药物相关风险。只有在潜在获益证明对母亲和胎儿的潜在风险合理的情况下，才应在妊娠期间使用Sotrovimab。</blockquote></p><p> <b>Lactation</b></p><p><blockquote><b>哺乳期</b></blockquote></p><p> There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p><p><blockquote>目前尚无关于索曲维单抗在母乳中的存在、对母乳喂养婴儿的影响或对乳汁分泌的影响的数据。正在母乳喂养的新冠肺炎患者应遵循临床指南的做法，以避免婴儿接触新冠肺炎。</blockquote></p><p> <b>About the GSK and Vir collaboration</b></p><p><blockquote><b>关于葛兰素史克与 Vir 的合作</b></blockquote></p><p> In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p><p><blockquote>2020 年 4 月，葛兰素史克和 Vir 合作研究和开发冠状病毒解决方案，包括导致 COVID-19 的 SARS-CoV-2 病毒。此次合作利用 Vir 专有的单克隆抗体平台技术来加速现有的抗病毒抗体，并确定新的抗病毒抗体，这些抗体可用作治疗或预防方案，以帮助应对当前的 COVID-19 大流行和未来的疫情。两家公司将利用葛兰素史克在功能基因组学方面的专业知识，结合其在 CRISPR 筛选和人工智能方面的能力，以识别针对细胞宿主基因的抗冠状病毒化合物。他们还将运用他们的综合专业知识来研究新型冠状病毒和其他冠状病毒疫苗。</blockquote></p><p> <b>GSK commitment to tackling COVID-19</b></p><p><blockquote><b>葛兰素史克致力于应对 COVID-19</b></blockquote></p><p> GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p><p><blockquote>葛兰素史克对 COVID-19 的回应是业内最广泛的回应之一，除了我们与合作伙伴机构开发的候选疫苗外，还有潜在的治疗方法。</blockquote></p><p> GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p><p><blockquote>葛兰素史克正在通过提供我们的佐剂技术，与多个组织合作研发新冠肺炎疫苗。我们正在与Sanofi S.A.、Medicago Inc.和SK bioscience Co., Ltd.合作开发佐剂、基于蛋白质的候选疫苗，目前所有疫苗都处于III期临床试验阶段。佐剂的使用在疫情中可能特别重要，因为它可以减少每剂所需的疫苗蛋白量，允许生产更多疫苗剂量，并有助于保护更多有需要的人。</blockquote></p><p> GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p><p><blockquote>葛兰素史克还与mRNA专家CureVac N.V.合作，共同开发针对新冠肺炎的下一代优化mRNA疫苗，有可能在一种疫苗中解决多种新兴变异。</blockquote></p><p> GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p><p><blockquote>葛兰素史克还在探索针对 COVID-19 患者的治疗方法，与 Vir Biotechnology 合作研究可用作 COVID-19 治疗或预防选择的单克隆抗体。</blockquote></p><p> <b>Vir’s commitment to COVID-19</b></p><p><blockquote><b>Vir对COVID-19的承诺</b></blockquote></p><p> Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p><p><blockquote>Vir 的成立宗旨是解决世界上最严重的传染病问题。2020 年，Vir 利用我们独特的科学见解和行业领先的抗体平台，探索多种单克隆抗体作为 COVID-19 的潜在治疗或预防选择，迅速应对 COVID-19 疫情。Sotrovimab是第一个推进到临床的SARS-CoV-2靶向抗体Vir。它是经过精心挑选的，因为它在临床前研究中证明的前景，包括预期的高耐药屏障和阻止病毒进入健康细胞和清除受感染细胞的潜在能力。Vir将继续寻求新的治疗和预防解决方案，以对抗新型冠状病毒和未来的冠状病毒大流行，无论是独立还是与其合作伙伴合作。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197973971","content_text":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.\nGeorge Scangos, PhD, Chief Executive Officer of Vir, said:“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”\nDr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”\nAbout sotrovimab\nSotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.\nUpdated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).\nAbout the sotrovimab clinical development programme\n\nCOMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published inThe New England Journal of Medicineon 27 October 2021 and final data were pre-published on 8 November 2021 onmedRxiv.\nCOMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.\nCOMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.\nGSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.\n\nAbout global access to sotrovimab\n\nSotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.\nGSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe\nCOVID-19.\nSotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.\n\nSotrovimab in the United States\nThe following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.\nSotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.\nSotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nAuthorized Use\nThe U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\nLimitations of Authorized Use\nSotrovimab is not authorized for use in patients:\n\nwho are hospitalized due to COVID-19, OR\nwho require oxygen therapy due to COVID-19, OR\nwho require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)\n\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.\nImportant Safety Information\nCONTRAINDICATIONS\nSotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.\nWARNINGS AND PRECAUTIONS\nThere are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.\nHypersensitivity Including Anaphylaxis and Infusion-Related Reactions\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.\nInfusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.\nSigns and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.\nConsider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.\nHypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.\nClinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration\nClinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.\nLimitations of Benefit and Potential for Risk in Patients with Severe COVID‑19\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.\nADVERSE EVENTS\nHypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.\nThe most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.\nUSE IN SPECIFIC POPULATIONS\nPregnancy\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\nLactation\nThere are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.\nAbout the GSK and Vir collaboration\nIn April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.\nGSK commitment to tackling COVID-19\nGSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.\nGSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.\nGSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.\nGSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.\nVir’s commitment to COVID-19\nVir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.","news_type":1,"symbols_score_info":{"GSK":0.9}},"isVote":1,"tweetType":1,"viewCount":1117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603296703,"gmtCreate":1638410588424,"gmtModify":1638411653816,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Wow nice&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Wow nice&nbsp;","text":"$NIO Inc.(NIO)$Wow nice","images":[{"img":"https://static.tigerbbs.com/3a0591c0af408d2bcb44249410443119","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603296703","isVote":1,"tweetType":1,"viewCount":1321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":603296500,"gmtCreate":1638410565001,"gmtModify":1638411652143,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Bit by bit&nbsp;","listText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Bit by bit&nbsp;","text":"$Twitter(TWTR)$Bit by bit","images":[{"img":"https://static.tigerbbs.com/b931c06a48ec84e2f073e462cba6d3a2","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603296500","isVote":1,"tweetType":1,"viewCount":1397,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":603206701,"gmtCreate":1638409788671,"gmtModify":1638410379523,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603206701","repostId":"1187224831","repostType":4,"isVote":1,"tweetType":1,"viewCount":1390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":890329059,"gmtCreate":1628084347171,"gmtModify":1633753769296,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"[Tongue]&nbsp;","listText":"[Tongue]&nbsp;","text":"[Tongue]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/890329059","repostId":"1146704714","repostType":4,"repost":{"id":"1146704714","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628083681,"share":"https://www.laohunote.com/m/news/1146704714?lang=zh_CN&edition=full","pubTime":"2021-08-04 21:28","market":"us","language":"en","title":"Stocks open slightly lower after ADP private-sector payrolls data<blockquote>ADP 私营部门就业数据公布后，股市小幅开盘走低</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1146704714","media":"Tiger Newspress","summary":"Stocks open slightly lower after ADP private-sector payrolls data\nAirline stocks, bank stocks fell. ","content":"<p><ul>  <li>Stocks open slightly lower after ADP private-sector payrolls data</li>  <li>Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</li>  <li>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.</li> </ul> (Aug 4)&nbsp;U.S. stocks fell on Wednesday morning after the earnings of a major automaker and a private sector jobs report came in lower than expected.</p><p><blockquote><ul><li>ADP 私营部门就业数据公布后，股市小幅开盘走低</li><li>航空股、银行股下跌。中国股市上涨。</li><li>由于盈利令人失望，通用汽车股价下跌超过 6%。</li></ul>（8月4日）美国周三上午，一家主要汽车制造商的盈利和私营部门的就业报告低于预期，股市下跌。</blockquote></p><p> The Dow Jones Industrial Average shed about 147 points, or 0.4%. The S&amp;P 500 slipped by 0.3% while the Nasdaq Composite was flat. The dip comes after the S&amp;P 500 broke a 2-day losing streak on Tuesday to post a record close, bringing its 2021 gains to more than 17%.&nbsp;</p><p><blockquote>道琼斯工业平均指数下跌约 147 点，跌幅 0.4%。标普500指数下跌 0.3%，而纳斯达克综合指数持平。此前，标普500周二打破了连续两天的下跌，创下历史新高，2021 年涨幅超过 17%。</blockquote></p><p> Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</p><p><blockquote>航空股、银行股下跌。中国股市上涨。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f07059e6f35af7ae40b84ff4fccdc425\" tg-width=\"364\" tg-height=\"369\" referrerpolicy=\"no-referrer\"><span>Airline stocks fell</span></p><p><blockquote><p class=\"t-img-caption\"><span>航空股下跌</span></p></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1616caf96bbfd7781bd83ec905dadfb4\" tg-width=\"359\" tg-height=\"652\" referrerpolicy=\"no-referrer\"><span>Bank stocks are down</span></p><p><blockquote><p class=\"t-img-caption\"><span>银行股下跌</span></p></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/342fe79f0fe76a05734e9a553bf3d22e\" tg-width=\"365\" tg-height=\"715\" referrerpolicy=\"no-referrer\"><span>Chinese Stocks rally</span></p><p><blockquote><p class=\"t-img-caption\"><span>中国股市上涨</span></p></blockquote></p><p> Novavax Stock Jumps After Europe Approves Contract for Covid Vaccine.</p><p><blockquote>欧洲批准新冠疫苗合同后，Novavax 股价上涨。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3da91666091c7ee912199acb975944a2\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.&nbsp;</b>Shares of General Motors fell about 6% in early trading, weighing on the broader market, after the automakermissed earnings expectations for the second quarter. The automaker did raise its guidance for a key profit metric for the rest of the year.</p><p><blockquote><b>由于盈利令人失望，通用汽车股价下跌超过 6%。</b>通用汽车股价在早盘交易中下跌约 6%，令大盘承压，此前该汽车制造商第二季度盈利未达到预期。该汽车制造商确实提高了今年剩余时间关键利润指标的指引。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a83eef22ad4c7b4513849130b478e6b7\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks open slightly lower after ADP private-sector payrolls data<blockquote>ADP 私营部门就业数据公布后，股市小幅开盘走低</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks open slightly lower after ADP private-sector payrolls data<blockquote>ADP 私营部门就业数据公布后，股市小幅开盘走低</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-04 21:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><ul>  <li>Stocks open slightly lower after ADP private-sector payrolls data</li>  <li>Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</li>  <li>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.</li> </ul> (Aug 4)&nbsp;U.S. stocks fell on Wednesday morning after the earnings of a major automaker and a private sector jobs report came in lower than expected.</p><p><blockquote><ul><li>ADP 私营部门就业数据公布后，股市小幅开盘走低</li><li>航空股、银行股下跌。中国股市上涨。</li><li>由于盈利令人失望，通用汽车股价下跌超过 6%。</li></ul>（8月4日）美国周三上午，一家主要汽车制造商的盈利和私营部门的就业报告低于预期，股市下跌。</blockquote></p><p> The Dow Jones Industrial Average shed about 147 points, or 0.4%. The S&amp;P 500 slipped by 0.3% while the Nasdaq Composite was flat. The dip comes after the S&amp;P 500 broke a 2-day losing streak on Tuesday to post a record close, bringing its 2021 gains to more than 17%.&nbsp;</p><p><blockquote>道琼斯工业平均指数下跌约 147 点，跌幅 0.4%。标普500指数下跌 0.3%，而纳斯达克综合指数持平。此前，标普500周二打破了连续两天的下跌，创下历史新高，2021 年涨幅超过 17%。</blockquote></p><p> Airline&nbsp;stocks,&nbsp;bank&nbsp;stocks&nbsp;fell.&nbsp;Chinese Stocks&nbsp;rally.</p><p><blockquote>航空股、银行股下跌。中国股市上涨。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f07059e6f35af7ae40b84ff4fccdc425\" tg-width=\"364\" tg-height=\"369\" referrerpolicy=\"no-referrer\"><span>Airline stocks fell</span></p><p><blockquote><p class=\"t-img-caption\"><span>航空股下跌</span></p></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1616caf96bbfd7781bd83ec905dadfb4\" tg-width=\"359\" tg-height=\"652\" referrerpolicy=\"no-referrer\"><span>Bank stocks are down</span></p><p><blockquote><p class=\"t-img-caption\"><span>银行股下跌</span></p></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/342fe79f0fe76a05734e9a553bf3d22e\" tg-width=\"365\" tg-height=\"715\" referrerpolicy=\"no-referrer\"><span>Chinese Stocks rally</span></p><p><blockquote><p class=\"t-img-caption\"><span>中国股市上涨</span></p></blockquote></p><p> Novavax Stock Jumps After Europe Approves Contract for Covid Vaccine.</p><p><blockquote>欧洲批准新冠疫苗合同后，Novavax 股价上涨。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3da91666091c7ee912199acb975944a2\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>GM fell&nbsp;over&nbsp;6%&nbsp;as&nbsp;earnings disappoint.&nbsp;</b>Shares of General Motors fell about 6% in early trading, weighing on the broader market, after the automakermissed earnings expectations for the second quarter. The automaker did raise its guidance for a key profit metric for the rest of the year.</p><p><blockquote><b>由于盈利令人失望，通用汽车股价下跌超过 6%。</b>通用汽车股价在早盘交易中下跌约 6%，令大盘承压，此前该汽车制造商第二季度盈利未达到预期。该汽车制造商确实提高了今年剩余时间关键利润指标的指引。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a83eef22ad4c7b4513849130b478e6b7\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146704714","content_text":"Stocks open slightly lower after ADP private-sector payrolls data\nAirline stocks, bank stocks fell. Chinese Stocks rally.\nGM fell over 6% as earnings disappoint.\n\n(Aug 4) U.S. stocks fell on Wednesday morning after the earnings of a major automaker and a private sector jobs report came in lower than expected.\nThe Dow Jones Industrial Average shed about 147 points, or 0.4%. The S&P 500 slipped by 0.3% while the Nasdaq Composite was flat. The dip comes after the S&P 500 broke a 2-day losing streak on Tuesday to post a record close, bringing its 2021 gains to more than 17%. \nAirline stocks, bank stocks fell. Chinese Stocks rally.\nAirline stocks fell\nBank stocks are down\nChinese Stocks rally\nNovavax Stock Jumps After Europe Approves Contract for Covid Vaccine.\n\nGM fell over 6% as earnings disappoint. Shares of General Motors fell about 6% in early trading, weighing on the broader market, after the automakermissed earnings expectations for the second quarter. The automaker did raise its guidance for a key profit metric for the rest of the year.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,"SPY":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884672632,"gmtCreate":1631890123326,"gmtModify":1632805531773,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"🥰🥰🥰🥰","listText":"🥰🥰🥰🥰","text":"🥰🥰🥰🥰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884672632","repostId":"1172069384","repostType":4,"repost":{"id":"1172069384","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631888749,"share":"https://www.laohunote.com/m/news/1172069384?lang=zh_CN&edition=full","pubTime":"2021-09-17 22:25","market":"us","language":"en","title":"Zoom Video Stock rose 2% in morning trading<blockquote>Zoom Video股价早盘上涨 2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172069384","media":"Tiger Newspress","summary":"Zoom Video Stock rose 2% in morning trading on report ISS urged Five9 holders to reject takeover bid","content":"<p>Zoom Video Stock rose 2% in morning trading&nbsp;on report ISS urged Five9 holders to reject takeover bid.</p><p><blockquote>有报道称 ISS 敦促 Five9 股东拒绝收购要约，Zoom Video股价在早盘交易中上涨 2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0848666fe26a30e300c95e7d49279fb1\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Proxy advisory firm Institutional Shareholder Services on Friday recommended a vote by shareholders against&nbsp;Zoom&nbsp;Video Communications Inc's $14.7 billion deal for cloud-based call center operator&nbsp;Five9 Inc, citing growth concerns.</p><p><blockquote>代理咨询公司Institutional Shareholder Services周五建议股东投票反对Zoom Video通信公司以147亿美元收购基于云的看涨期权中心运营商Five9 Inc.，理由是增长担忧。</blockquote></p><p> Though the combined company will have access to a larger market,ISS&nbsp;said, \"The all-stock deal exposes Five9 shareholders to a more volatile stock whose growth prospects have become less compelling as society inches towards a post-pandemic environment.\"</p><p><blockquote>ISS 表示，尽管合并后的公司将能够进入更大的市场，但“全股票交易使 Five9 股东接触到一只波动性更大的股票，随着社会迈向大流行后环境，该股票的增长前景变得不那么令人信服。”</blockquote></p><p> Since the deal was announced on July 18, Zoom shares have lost more than 20% of their value, while Five9 has dipped about 5%.</p><p><blockquote>自 7 月 18 日宣布该交易以来，Zoom 股价已下跌超过 20%，而 Five9 则下跌约 5%。</blockquote></p><p> A pandemic winner whose shares had surged nearly 396% last year, Zoom struck its largest-ever acquisition for Five9 in a bid to expand beyond its core video-conferencing services.</p><p><blockquote>作为去年股价飙升近 396% 的大流行赢家，Zoom 对 Five9 进行了有史以来最大的收购，以扩展到其核心视频会议服务之外。</blockquote></p><p> The company earlier this month announced improvements and expansions to its services that included event lobbies, chat, networking in the hope that consumers will continue to use its platform for remote-working.</p><p><blockquote>该公司本月早些时候宣布改进和扩展其服务，包括活动大厅、聊天、网络，希望消费者能够继续使用其平台进行远程工作。</blockquote></p><p> However, ISS said the new additions failed to assuage shareholder concerns of continued business churn, while Five9's prospects have improved since the acquisition was announced and could attract more bidders if the deal falls apart.</p><p><blockquote>然而，ISS表示，新的增加未能缓解股东对业务持续流失的担忧，而Five9的前景自收购宣布以来有所改善，如果交易失败，可能会吸引更多竞标者。</blockquote></p><p> Zoom and Five9 were not immediately available for a comment.</p><p><blockquote>Zoom 和 Five9 未能立即置评。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Video Stock rose 2% in morning trading<blockquote>Zoom Video股价早盘上涨 2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Video Stock rose 2% in morning trading<blockquote>Zoom Video股价早盘上涨 2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-17 22:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Zoom Video Stock rose 2% in morning trading&nbsp;on report ISS urged Five9 holders to reject takeover bid.</p><p><blockquote>有报道称 ISS 敦促 Five9 股东拒绝收购要约，Zoom Video股价在早盘交易中上涨 2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0848666fe26a30e300c95e7d49279fb1\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Proxy advisory firm Institutional Shareholder Services on Friday recommended a vote by shareholders against&nbsp;Zoom&nbsp;Video Communications Inc's $14.7 billion deal for cloud-based call center operator&nbsp;Five9 Inc, citing growth concerns.</p><p><blockquote>代理咨询公司Institutional Shareholder Services周五建议股东投票反对Zoom Video通信公司以147亿美元收购基于云的看涨期权中心运营商Five9 Inc.，理由是增长担忧。</blockquote></p><p> Though the combined company will have access to a larger market,ISS&nbsp;said, \"The all-stock deal exposes Five9 shareholders to a more volatile stock whose growth prospects have become less compelling as society inches towards a post-pandemic environment.\"</p><p><blockquote>ISS 表示，尽管合并后的公司将能够进入更大的市场，但“全股票交易使 Five9 股东接触到一只波动性更大的股票，随着社会迈向大流行后环境，该股票的增长前景变得不那么令人信服。”</blockquote></p><p> Since the deal was announced on July 18, Zoom shares have lost more than 20% of their value, while Five9 has dipped about 5%.</p><p><blockquote>自 7 月 18 日宣布该交易以来，Zoom 股价已下跌超过 20%，而 Five9 则下跌约 5%。</blockquote></p><p> A pandemic winner whose shares had surged nearly 396% last year, Zoom struck its largest-ever acquisition for Five9 in a bid to expand beyond its core video-conferencing services.</p><p><blockquote>作为去年股价飙升近 396% 的大流行赢家，Zoom 对 Five9 进行了有史以来最大的收购，以扩展到其核心视频会议服务之外。</blockquote></p><p> The company earlier this month announced improvements and expansions to its services that included event lobbies, chat, networking in the hope that consumers will continue to use its platform for remote-working.</p><p><blockquote>该公司本月早些时候宣布改进和扩展其服务，包括活动大厅、聊天、网络，希望消费者能够继续使用其平台进行远程工作。</blockquote></p><p> However, ISS said the new additions failed to assuage shareholder concerns of continued business churn, while Five9's prospects have improved since the acquisition was announced and could attract more bidders if the deal falls apart.</p><p><blockquote>然而，ISS表示，新的增加未能缓解股东对业务持续流失的担忧，而Five9的前景自收购宣布以来有所改善，如果交易失败，可能会吸引更多竞标者。</blockquote></p><p> Zoom and Five9 were not immediately available for a comment.</p><p><blockquote>Zoom 和 Five9 未能立即置评。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172069384","content_text":"Zoom Video Stock rose 2% in morning trading on report ISS urged Five9 holders to reject takeover bid.\n\nProxy advisory firm Institutional Shareholder Services on Friday recommended a vote by shareholders against Zoom Video Communications Inc's $14.7 billion deal for cloud-based call center operator Five9 Inc, citing growth concerns.\nThough the combined company will have access to a larger market,ISS said, \"The all-stock deal exposes Five9 shareholders to a more volatile stock whose growth prospects have become less compelling as society inches towards a post-pandemic environment.\"\nSince the deal was announced on July 18, Zoom shares have lost more than 20% of their value, while Five9 has dipped about 5%.\nA pandemic winner whose shares had surged nearly 396% last year, Zoom struck its largest-ever acquisition for Five9 in a bid to expand beyond its core video-conferencing services.\nThe company earlier this month announced improvements and expansions to its services that included event lobbies, chat, networking in the hope that consumers will continue to use its platform for remote-working.\nHowever, ISS said the new additions failed to assuage shareholder concerns of continued business churn, while Five9's prospects have improved since the acquisition was announced and could attract more bidders if the deal falls apart.\nZoom and Five9 were not immediately available for a comment.","news_type":1,"symbols_score_info":{"ZM":0.9}},"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":601210045,"gmtCreate":1638533688808,"gmtModify":1638533703139,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601210045","repostId":"1144924535","repostType":4,"repost":{"id":"1144924535","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638533072,"share":"https://www.laohunote.com/m/news/1144924535?lang=zh_CN&edition=full","pubTime":"2021-12-03 20:04","market":"us","language":"en","title":"Moderna stock jumped more than 5% in premarket trading<blockquote>Moderna 股价在盘前交易中上涨超过 5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144924535","media":"老虎资讯综合","summary":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in","content":"<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p><p><blockquote>Moderna 股票在盘前交易中上涨超过 5%，因为 Moderna 在英国 COVID-19 加强试验中的抗体反应领先..</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p><p><blockquote>根据发表在<i>柳叶刀</i>周四，Moderna新冠肺炎疫苗在一项评估新冠肺炎疫苗作为加强剂的不同组合的试验中显示出最强的抗体效果。</blockquote></p><p> The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p><p><blockquote>在英国18个不同地点进行的第二阶段“COV-Boost”研究涉及近2900名30岁以上的人。研究中一半的人接种了两剂牛津-阿斯利康疫苗，其余的人接种了辉瑞/BioNTec疫苗。</blockquote></p><p> The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p><p><blockquote>该试验旨在评估阿斯利康、辉瑞/BioNTech、Novavax、强生、Moderna、Valneva和Curevac开发的七种加强疫苗的安全性和有效性。</blockquote></p><p> While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p><p><blockquote>虽然除 Valneva (VALN) 疫苗外，所有七种疫苗都能增强最初接种辉瑞/ BioNTech 疫苗的人的免疫力，但在阿斯利康疫苗初始治疗方案 10-12 周后接种时，所有七种疫苗都能提高免疫水平。</blockquote></p><p> Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p><p><blockquote>值得注意的是，Moderna COVID-19注射产生了最强的加强效应，导致阿斯利康组的抗体水平上升超过32倍，辉瑞/BioNTech组的抗体水平上升超过11倍，<i>卫报</i>报道。</blockquote></p><p> In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p><p><blockquote>此外，英国周三表示，已同意再购买 1.14 亿支辉瑞/BioNTech 和 Moderna COVID-19 疫苗，并表示鉴于新奥密克戎变种的出现，英国已加快签署新合同。</blockquote></p><p> The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p><p><blockquote>英国卫生部表示，该协议涉及明年和 2023 年额外提供 6000 万剂 Moderna 疫苗和 5400 万剂辉瑞疫苗，如果需要对抗奥密克戎毒株或任何其他变种，还将包括获得任何改良疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped more than 5% in premarket trading<blockquote>Moderna 股价在盘前交易中上涨超过 5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped more than 5% in premarket trading<blockquote>Moderna 股价在盘前交易中上涨超过 5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-12-03 20:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock jumped more than 5% in premarket trading&nbsp;because&nbsp;Moderna led with antibody response in COVID-19 booster trial in U.K..</p><p><blockquote>Moderna 股票在盘前交易中上涨超过 5%，因为 Moderna 在英国 COVID-19 加强试验中的抗体反应领先..</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> According to a peer-reviewed study published in&nbsp;<i>The Lancet</i>&nbsp;on Thursday, Moderna&nbsp;COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p><p><blockquote>根据发表在<i>柳叶刀</i>周四，Moderna新冠肺炎疫苗在一项评估新冠肺炎疫苗作为加强剂的不同组合的试验中显示出最强的抗体效果。</blockquote></p><p> The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca&nbsp;vaccine, and the rest had received the Pfizer/BioNTec&nbsp;vaccine.</p><p><blockquote>在英国18个不同地点进行的第二阶段“COV-Boost”研究涉及近2900名30岁以上的人。研究中一半的人接种了两剂牛津-阿斯利康疫苗，其余的人接种了辉瑞/BioNTec疫苗。</blockquote></p><p> The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson &amp; Johnson, Moderna, Valneva&nbsp;and Curevac.</p><p><blockquote>该试验旨在评估阿斯利康、辉瑞/BioNTech、Novavax、强生、Moderna、Valneva和Curevac开发的七种加强疫苗的安全性和有效性。</blockquote></p><p> While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca&nbsp;vaccine.</p><p><blockquote>虽然除 Valneva (VALN) 疫苗外，所有七种疫苗都能增强最初接种辉瑞/ BioNTech 疫苗的人的免疫力，但在阿斯利康疫苗初始治疗方案 10-12 周后接种时，所有七种疫苗都能提高免疫水平。</blockquote></p><p> Notably, Moderna&nbsp;COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca&nbsp;group and over 11-fold increase in the Pfizer/ BioNTech&nbsp;group,&nbsp;<i>The Guardian</i>&nbsp;reported.</p><p><blockquote>值得注意的是，Moderna COVID-19注射产生了最强的加强效应，导致阿斯利康组的抗体水平上升超过32倍，辉瑞/BioNTech组的抗体水平上升超过11倍，<i>卫报</i>报道。</blockquote></p><p> In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p><p><blockquote>此外，英国周三表示，已同意再购买 1.14 亿支辉瑞/BioNTech 和 Moderna COVID-19 疫苗，并表示鉴于新奥密克戎变种的出现，英国已加快签署新合同。</blockquote></p><p> The deal involves an additional 60 million Moderna&nbsp;shots and 54 million Pfizer&nbsp;doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p><p><blockquote>英国卫生部表示，该协议涉及明年和 2023 年额外提供 6000 万剂 Moderna 疫苗和 5400 万剂辉瑞疫苗，如果需要对抗奥密克戎毒株或任何其他变种，还将包括获得任何改良疫苗。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144924535","content_text":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..\n\nAccording to a peer-reviewed study published in The Lancet on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.\nThe Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.\nThe trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.\nWhile all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.\nNotably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, The Guardian reported.\nIn addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.\nThe deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873461782,"gmtCreate":1636978021684,"gmtModify":1636978022119,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>Ddd","listText":"<a href=\"https://laohu8.com/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>Ddd","text":"$SINGAPORE EXCHANGE LIMITED(S68.SI)$Ddd","images":[{"img":"https://static.tigerbbs.com/516b780597444df30d5763000807b54b","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/873461782","isVote":1,"tweetType":1,"viewCount":1003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861873972,"gmtCreate":1632488121596,"gmtModify":1632718459090,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/861873972","repostId":"1142559059","repostType":4,"repost":{"id":"1142559059","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632484839,"share":"https://www.laohunote.com/m/news/1142559059?lang=zh_CN&edition=full","pubTime":"2021-09-24 20:00","market":"us","language":"en","title":"Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142559059","media":"Tiger Newspress","summary":"(Sept 24) Stock futures gave back gains after equities' best day since July.\nAt 08:01 a.m. ET, Dow e","content":"<p>(Sept 24)&nbsp;Stock futures gave back gains after equities' best day since July.</p><p><blockquote>（9月24日）在股市经历了7月以来最好的一天后，股票期货回吐了涨幅。</blockquote></p><p> At 08:01 a.m. ET, Dow e-minis were down 149 points, or 0.43%, S&amp;P 500 e-minis fell 22.75 points, or 0.51%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis sank 106.5&nbsp;points, or 0.70%.</p><p><blockquote>美国东部时间上午 08:01，道琼斯电子迷你指数下跌 149 点，跌幅 0.43%，标普500电子迷你指数下跌 22.75 点，跌幅 0.51%，<a href=\"https://laohu8.com/S/NDAQ\">纳斯达克</a>100 E-mini 下跌 106.5 点，跌幅 0.70%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/30a653559f88adfa0843eba93e9dc775\" tg-width=\"1242\" tg-height=\"493\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cryptocurrency-exposed stocks slumped in U.S.&nbsp;premarket&nbsp;trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%.</p><p><blockquote>加密货币敞口股票在美国盘前交易中暴跌。Marathon Digital (MARA) 下跌 6.5%，Bit Digital (BTBT) 下跌 4.7%，Riot Blockchain (RIOT) 下跌 5.9%，Coinbase 下跌 2.8%。</blockquote></p><p> Big banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits.</p><p><blockquote>摩根大通、花旗集团、摩根士丹利和美国银行等大银行在盘前交易中下跌约0.5%，石油巨头埃克森美孚和雪佛龙公司分别下跌0.4%和0.3%。大型FAAMG科技巨头跌幅在0.5%至0.6%之间。耐克下跌 4.6%，此前这家运动服装制造商下调了 2022 财年的销售预期，并警告假日购物季将出现延误。在这家运动服装和运动鞋制造商将财年收入增长指引下调至中个位数后，几位分析师下调了该公司的目标价。</blockquote></p><p> <b>Stocks making the biggest moves premarket:</b></p><p><blockquote><b>盘前波动最大的股票：</b></blockquote></p><p> Robinhood(HOOD),Coinbase(COIN) -- Shares of the retail trading app and cryptocurrency exchange fell in premarket trading after China signaled that it was intensifying its crackdown on crypto.The country's central bank said Friday that all cryptocurrency-related activities are illegal. Shares of Coinbase fell more than 3.6% while Robinhood dropped 2%.</p><p><blockquote>Robinhood (HOOD)、Coinbase (COIN) -- 在中国表示正在加强对加密货币的打压后，零售交易应用程序和加密货币交易所的股价在盘前交易中下跌。该国央行周五表示，所有与加密货币相关的活动都是非法的。Coinbase 股价下跌超过 3.6%，Robinhood 下跌 2%。</blockquote></p><p> Roku(ROKU) — Shares of the streaming video platform fell in premarket trading afterWells Fargo downgraded Roku to equal weight from overweight. The investment firm said in a note that Wall Street expectations for Roku's revenue growth are likely too high as competition increases. Shares of Roku were down 2.3%.</p><p><blockquote>Roku（Roku）——在富国银行将Roku的评级从跑赢大盘下调至同等权重后，流媒体视频平台的股价在盘前交易中下跌。该投资公司在一份报告中表示，随着竞争的加剧，华尔街对 Roku 收入增长的预期可能过高。Roku股价下跌 2.3%。</blockquote></p><p> Nike(NKE) — The apparel giant’s stock was under pressure on Friday afterNike cut its revenue forecasts due to supply chain issues.The company said it expects full-year sales growth in the mid-single digits for the 2022 fiscal year, down from a previous forecast of low double-digit growth. Shares of Nike fell more than 4% in premarket trading.</p><p><blockquote>耐克（NKE）--周五，耐克因供应链问题下调了收入预期，这家服装巨头的股价承压。该公司表示，预计 2022 财年全年销售额增长将达到中个位数，低于之前预测的低两位数增长。耐克股价在盘前交易中下跌超过 4%。</blockquote></p><p> Under Armour(UAA) — The athletic apparel retailer’s stock fell in premarket trading after rival Nike cut its guidance. Shares of Under Armour were down more than 2% in premarket trading.</p><p><blockquote>Under Armour（UAA）--在竞争对手耐克下调指引后，这家运动服装零售商的股价在盘前交易中下跌。Under Armour 股价在盘前交易中下跌超过 2%。</blockquote></p><p> Costco(COST) — The retailer beat expectations on the top and bottom lines in its fiscal fourth-quarter report on Thursday afternoon. The company reported $3.90 in adjusted earnings per share, easily topping expectations of $3.57, and net sales for the quarter rose more than 17% year over year. The stock was slightly higher in premarket trading.</p><p><blockquote>好市多（COST）——该零售商周四下午发布的第四财季报告的营收和利润超出了预期。该公司公布调整后每股收益为 3.90 美元，轻松超过预期的 3.57 美元，本季度净销售额同比增长超过 17%。该股在盘前交易中小幅走高。</blockquote></p><p> Merck(MRK) — The pharmaceutical giant, along withAstraZeneca, announced on Friday morning that a treatment using the drug Lynparza slowed the progression of prostate cancer in a phase three trial. Shares of Merck rose more than 1% in premarket trading.</p><p><blockquote>默克公司（MRK）——这家制药巨头与阿斯利康一起于周五上午宣布，在一项三期试验中，使用药物 Lynparza 的治疗减缓了前列腺癌的进展。默克股价在盘前交易中上涨超过 1%。</blockquote></p><p> Cheesecake Factory(CAKE),Dave &amp; Buster's(PLAY) — The restaurant stocks rose slightly in premarket trading after Jefferies upgraded the stocks to buy from hold. The firm said that full-service restaurants have seen traffic hold up well despite the spread of the delta variant.</p><p><blockquote>Cheesecake Factory (CAKE)、Dave &amp; Buster's (PLAY) — Jefferies 将该股评级从持有上调至买入后，该餐厅股票在盘前交易中小幅上涨。该公司表示，尽管德尔塔变异毒株蔓延，但提供全方位服务的餐厅的客流量保持良好。</blockquote></p><p> Helbiz (HLBZ) — Helbiz&nbsp;falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders.</p><p><blockquote>Helbiz (HLBZ) — Helbiz 下跌 10%，此前这家微移动公司向 SEC 提交了股东出售多达 1100 万股股票的申请。</blockquote></p><p> Focus Universal (FCUV), —&nbsp;Focus Universal&nbsp;an online marketing company that’s been a favorite of retail traders, surged 26% in&nbsp;premarket&nbsp;trading after the stock was cited on Stocktwits in recent days.</p><p><blockquote>Focus Universal (FCUV) - Focus Universal 是一家深受零售商喜爱的在线营销公司，在最近几天 Stocktwits 上引用该股后，该股在盘前交易中大涨 26%。</blockquote></p><p> Vail Resorts (MTN) — Vail Resorts&nbsp;falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint.</p><p><blockquote>维尔度假村 (MTN) — 维尔度假村在盘后交易中下跌 2.7%，此前其全年 Ebitda 和净利润预测未达到中点。</blockquote></p><p> GlycoMimetics (GLYC) — GlycoMimetics&nbsp;jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16.</p><p><blockquote>GlycoMimetics (GLYC) — GlycoMimetics 宣布 uproleselan 在急性髓性白血病患者中进行的 1/2 期研究的疗效和安全性数据于 9 月 16 日发表在《Blood》杂志上后，上市后股价上涨 15%。</blockquote></p><p> VTV Therapeutics (VTVT) —&nbsp;VTV Therapeutics&nbsp;surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. </p><p><blockquote>VTV Therapeutics (VTVT) — VTV Therapeutics 股价飙升 30%，此前该公司表示其 HPP737 银屑病治疗在一项多重递增剂量研究中显示出良好的安全性和耐受性。</blockquote></p><p></p><p> <b>In FX, </b>the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as&nbsp; businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support</p><p><blockquote><b>在外汇中，</b>彭博美元现货指数从一周低点回升，因对恒大可能传染的担忧增加了对美元的买盘，基于周三发出的美联储缩减时间表。新西兰元、澳元和加元在 G-10 记分牌上垫底。ZAR 和 TRY 是新兴市场外汇中最弱的。由于投资者期待英国央行行长安德鲁-贝利（Andrew Bailey）下周就可能加息发表讲话，英镑在周四反弹后下跌。交易员押注，在首先提高借贷成本的竞赛中，英国央行将成为战胜美联储的绝对赢家。新西兰元和澳元在10国集团同行中领跌。荷兰国际集团（ING）分析师弗朗切斯科-佩索莱（Francesco Pesole）和克里斯-特纳（Chris Turner）表示，欧元交易持平，本周事件频发，未能 “产生任何明确的方向性变动”。德国 IFO 情绪指数将 “提供有关该地区情绪的额外指标，因为企业面临着德尔塔变异毒株担忧和挥之不去的供应中断”。挪威克朗是本周 G10 货币中表现最好的货币，挪威银行周四宣布提供支持</blockquote></p><p> <b>In commodities,</b> crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal.</p><p><blockquote><b>在大宗商品方面，</b>原油期货在本周最佳水平附近窄幅上涨。WTI 停滞在 73.40 美元附近，布伦特原油停滞在 77.50 美元附近。现货黄金延续亚洲涨势，盘中上涨 12 美元，交易价格接近 1,755 美元/盎司。基本金属涨跌互现，LME 镍和铝下跌约 1%，LME 锡上涨 2.8%，跑赢大盘。中国人民银行表示所有与加密货币相关的交易都是非法的后，比特币下跌。</blockquote></p><p> Looking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan.</p><p><blockquote>展望未来，我们将听取美联储主席鲍威尔、副主席克拉里达和美联储的梅斯特、鲍曼、乔治和博斯蒂克，以及欧洲央行的莱恩和埃尔德森，以及英国央行的滕雷罗。最后，四方领导人峰会将在白宫举行，包括拜登总统以及澳大利亚、印度和日本的总理。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-24 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Sept 24)&nbsp;Stock futures gave back gains after equities' best day since July.</p><p><blockquote>（9月24日）在股市经历了7月以来最好的一天后，股票期货回吐了涨幅。</blockquote></p><p> At 08:01 a.m. ET, Dow e-minis were down 149 points, or 0.43%, S&amp;P 500 e-minis fell 22.75 points, or 0.51%, and <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100 e-minis sank 106.5&nbsp;points, or 0.70%.</p><p><blockquote>美国东部时间上午 08:01，道琼斯电子迷你指数下跌 149 点，跌幅 0.43%，标普500电子迷你指数下跌 22.75 点，跌幅 0.51%，<a href=\"https://laohu8.com/S/NDAQ\">纳斯达克</a>100 E-mini 下跌 106.5 点，跌幅 0.70%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/30a653559f88adfa0843eba93e9dc775\" tg-width=\"1242\" tg-height=\"493\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cryptocurrency-exposed stocks slumped in U.S.&nbsp;premarket&nbsp;trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%.</p><p><blockquote>加密货币敞口股票在美国盘前交易中暴跌。Marathon Digital (MARA) 下跌 6.5%，Bit Digital (BTBT) 下跌 4.7%，Riot Blockchain (RIOT) 下跌 5.9%，Coinbase 下跌 2.8%。</blockquote></p><p> Big banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits.</p><p><blockquote>摩根大通、花旗集团、摩根士丹利和美国银行等大银行在盘前交易中下跌约0.5%，石油巨头埃克森美孚和雪佛龙公司分别下跌0.4%和0.3%。大型FAAMG科技巨头跌幅在0.5%至0.6%之间。耐克下跌 4.6%，此前这家运动服装制造商下调了 2022 财年的销售预期，并警告假日购物季将出现延误。在这家运动服装和运动鞋制造商将财年收入增长指引下调至中个位数后，几位分析师下调了该公司的目标价。</blockquote></p><p> <b>Stocks making the biggest moves premarket:</b></p><p><blockquote><b>盘前波动最大的股票：</b></blockquote></p><p> Robinhood(HOOD),Coinbase(COIN) -- Shares of the retail trading app and cryptocurrency exchange fell in premarket trading after China signaled that it was intensifying its crackdown on crypto.The country's central bank said Friday that all cryptocurrency-related activities are illegal. Shares of Coinbase fell more than 3.6% while Robinhood dropped 2%.</p><p><blockquote>Robinhood (HOOD)、Coinbase (COIN) -- 在中国表示正在加强对加密货币的打压后，零售交易应用程序和加密货币交易所的股价在盘前交易中下跌。该国央行周五表示，所有与加密货币相关的活动都是非法的。Coinbase 股价下跌超过 3.6%，Robinhood 下跌 2%。</blockquote></p><p> Roku(ROKU) — Shares of the streaming video platform fell in premarket trading afterWells Fargo downgraded Roku to equal weight from overweight. The investment firm said in a note that Wall Street expectations for Roku's revenue growth are likely too high as competition increases. Shares of Roku were down 2.3%.</p><p><blockquote>Roku（Roku）——在富国银行将Roku的评级从跑赢大盘下调至同等权重后，流媒体视频平台的股价在盘前交易中下跌。该投资公司在一份报告中表示，随着竞争的加剧，华尔街对 Roku 收入增长的预期可能过高。Roku股价下跌 2.3%。</blockquote></p><p> Nike(NKE) — The apparel giant’s stock was under pressure on Friday afterNike cut its revenue forecasts due to supply chain issues.The company said it expects full-year sales growth in the mid-single digits for the 2022 fiscal year, down from a previous forecast of low double-digit growth. Shares of Nike fell more than 4% in premarket trading.</p><p><blockquote>耐克（NKE）--周五，耐克因供应链问题下调了收入预期，这家服装巨头的股价承压。该公司表示，预计 2022 财年全年销售额增长将达到中个位数，低于之前预测的低两位数增长。耐克股价在盘前交易中下跌超过 4%。</blockquote></p><p> Under Armour(UAA) — The athletic apparel retailer’s stock fell in premarket trading after rival Nike cut its guidance. Shares of Under Armour were down more than 2% in premarket trading.</p><p><blockquote>Under Armour（UAA）--在竞争对手耐克下调指引后，这家运动服装零售商的股价在盘前交易中下跌。Under Armour 股价在盘前交易中下跌超过 2%。</blockquote></p><p> Costco(COST) — The retailer beat expectations on the top and bottom lines in its fiscal fourth-quarter report on Thursday afternoon. The company reported $3.90 in adjusted earnings per share, easily topping expectations of $3.57, and net sales for the quarter rose more than 17% year over year. The stock was slightly higher in premarket trading.</p><p><blockquote>好市多（COST）——该零售商周四下午发布的第四财季报告的营收和利润超出了预期。该公司公布调整后每股收益为 3.90 美元，轻松超过预期的 3.57 美元，本季度净销售额同比增长超过 17%。该股在盘前交易中小幅走高。</blockquote></p><p> Merck(MRK) — The pharmaceutical giant, along withAstraZeneca, announced on Friday morning that a treatment using the drug Lynparza slowed the progression of prostate cancer in a phase three trial. Shares of Merck rose more than 1% in premarket trading.</p><p><blockquote>默克公司（MRK）——这家制药巨头与阿斯利康一起于周五上午宣布，在一项三期试验中，使用药物 Lynparza 的治疗减缓了前列腺癌的进展。默克股价在盘前交易中上涨超过 1%。</blockquote></p><p> Cheesecake Factory(CAKE),Dave &amp; Buster's(PLAY) — The restaurant stocks rose slightly in premarket trading after Jefferies upgraded the stocks to buy from hold. The firm said that full-service restaurants have seen traffic hold up well despite the spread of the delta variant.</p><p><blockquote>Cheesecake Factory (CAKE)、Dave &amp; Buster's (PLAY) — Jefferies 将该股评级从持有上调至买入后，该餐厅股票在盘前交易中小幅上涨。该公司表示，尽管德尔塔变异毒株蔓延，但提供全方位服务的餐厅的客流量保持良好。</blockquote></p><p> Helbiz (HLBZ) — Helbiz&nbsp;falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders.</p><p><blockquote>Helbiz (HLBZ) — Helbiz 下跌 10%，此前这家微移动公司向 SEC 提交了股东出售多达 1100 万股股票的申请。</blockquote></p><p> Focus Universal (FCUV), —&nbsp;Focus Universal&nbsp;an online marketing company that’s been a favorite of retail traders, surged 26% in&nbsp;premarket&nbsp;trading after the stock was cited on Stocktwits in recent days.</p><p><blockquote>Focus Universal (FCUV) - Focus Universal 是一家深受零售商喜爱的在线营销公司，在最近几天 Stocktwits 上引用该股后，该股在盘前交易中大涨 26%。</blockquote></p><p> Vail Resorts (MTN) — Vail Resorts&nbsp;falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint.</p><p><blockquote>维尔度假村 (MTN) — 维尔度假村在盘后交易中下跌 2.7%，此前其全年 Ebitda 和净利润预测未达到中点。</blockquote></p><p> GlycoMimetics (GLYC) — GlycoMimetics&nbsp;jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16.</p><p><blockquote>GlycoMimetics (GLYC) — GlycoMimetics 宣布 uproleselan 在急性髓性白血病患者中进行的 1/2 期研究的疗效和安全性数据于 9 月 16 日发表在《Blood》杂志上后，上市后股价上涨 15%。</blockquote></p><p> VTV Therapeutics (VTVT) —&nbsp;VTV Therapeutics&nbsp;surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. </p><p><blockquote>VTV Therapeutics (VTVT) — VTV Therapeutics 股价飙升 30%，此前该公司表示其 HPP737 银屑病治疗在一项多重递增剂量研究中显示出良好的安全性和耐受性。</blockquote></p><p></p><p> <b>In FX, </b>the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as&nbsp; businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support</p><p><blockquote><b>在外汇中，</b>彭博美元现货指数从一周低点回升，因对恒大可能传染的担忧增加了对美元的买盘，基于周三发出的美联储缩减时间表。新西兰元、澳元和加元在 G-10 记分牌上垫底。ZAR 和 TRY 是新兴市场外汇中最弱的。由于投资者期待英国央行行长安德鲁-贝利（Andrew Bailey）下周就可能加息发表讲话，英镑在周四反弹后下跌。交易员押注，在首先提高借贷成本的竞赛中，英国央行将成为战胜美联储的绝对赢家。新西兰元和澳元在10国集团同行中领跌。荷兰国际集团（ING）分析师弗朗切斯科-佩索莱（Francesco Pesole）和克里斯-特纳（Chris Turner）表示，欧元交易持平，本周事件频发，未能 “产生任何明确的方向性变动”。德国 IFO 情绪指数将 “提供有关该地区情绪的额外指标，因为企业面临着德尔塔变异毒株担忧和挥之不去的供应中断”。挪威克朗是本周 G10 货币中表现最好的货币，挪威银行周四宣布提供支持</blockquote></p><p> <b>In commodities,</b> crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal.</p><p><blockquote><b>在大宗商品方面，</b>原油期货在本周最佳水平附近窄幅上涨。WTI 停滞在 73.40 美元附近，布伦特原油停滞在 77.50 美元附近。现货黄金延续亚洲涨势，盘中上涨 12 美元，交易价格接近 1,755 美元/盎司。基本金属涨跌互现，LME 镍和铝下跌约 1%，LME 锡上涨 2.8%，跑赢大盘。中国人民银行表示所有与加密货币相关的交易都是非法的后，比特币下跌。</blockquote></p><p> Looking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan.</p><p><blockquote>展望未来，我们将听取美联储主席鲍威尔、副主席克拉里达和美联储的梅斯特、鲍曼、乔治和博斯蒂克，以及欧洲央行的莱恩和埃尔德森，以及英国央行的滕雷罗。最后，四方领导人峰会将在白宫举行，包括拜登总统以及澳大利亚、印度和日本的总理。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142559059","content_text":"(Sept 24) Stock futures gave back gains after equities' best day since July.\nAt 08:01 a.m. ET, Dow e-minis were down 149 points, or 0.43%, S&P 500 e-minis fell 22.75 points, or 0.51%, and Nasdaq 100 e-minis sank 106.5 points, or 0.70%.\n\nCryptocurrency-exposed stocks slumped in U.S. premarket trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%.\nBig banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits.\nStocks making the biggest moves premarket:\nRobinhood(HOOD),Coinbase(COIN) -- Shares of the retail trading app and cryptocurrency exchange fell in premarket trading after China signaled that it was intensifying its crackdown on crypto.The country's central bank said Friday that all cryptocurrency-related activities are illegal. Shares of Coinbase fell more than 3.6% while Robinhood dropped 2%.\nRoku(ROKU) — Shares of the streaming video platform fell in premarket trading afterWells Fargo downgraded Roku to equal weight from overweight. The investment firm said in a note that Wall Street expectations for Roku's revenue growth are likely too high as competition increases. Shares of Roku were down 2.3%.\nNike(NKE) — The apparel giant’s stock was under pressure on Friday afterNike cut its revenue forecasts due to supply chain issues.The company said it expects full-year sales growth in the mid-single digits for the 2022 fiscal year, down from a previous forecast of low double-digit growth. Shares of Nike fell more than 4% in premarket trading.\nUnder Armour(UAA) — The athletic apparel retailer’s stock fell in premarket trading after rival Nike cut its guidance. Shares of Under Armour were down more than 2% in premarket trading.\nCostco(COST) — The retailer beat expectations on the top and bottom lines in its fiscal fourth-quarter report on Thursday afternoon. The company reported $3.90 in adjusted earnings per share, easily topping expectations of $3.57, and net sales for the quarter rose more than 17% year over year. The stock was slightly higher in premarket trading.\nMerck(MRK) — The pharmaceutical giant, along withAstraZeneca, announced on Friday morning that a treatment using the drug Lynparza slowed the progression of prostate cancer in a phase three trial. Shares of Merck rose more than 1% in premarket trading.\nCheesecake Factory(CAKE),Dave & Buster's(PLAY) — The restaurant stocks rose slightly in premarket trading after Jefferies upgraded the stocks to buy from hold. The firm said that full-service restaurants have seen traffic hold up well despite the spread of the delta variant.\nHelbiz (HLBZ) — Helbiz falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders.\nFocus Universal (FCUV), — Focus Universal an online marketing company that’s been a favorite of retail traders, surged 26% in premarket trading after the stock was cited on Stocktwits in recent days.\nVail Resorts (MTN) — Vail Resorts falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint.\nGlycoMimetics (GLYC) — GlycoMimetics jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16.\nVTV Therapeutics (VTVT) — VTV Therapeutics surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. \nIn FX, the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as  businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support\nIn commodities, crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal.\nLooking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan.","news_type":1,"symbols_score_info":{".SPX":0.9,"SPY":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":799,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889709925,"gmtCreate":1631175361667,"gmtModify":1631883916102,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"All Red ( Red is the colour of luck) 💋💋💋","listText":"All Red ( Red is the colour of luck) 💋💋💋","text":"All Red ( Red is the colour of luck) 💋💋💋","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/889709925","repostId":"1176538965","repostType":4,"repost":{"id":"1176538965","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631174811,"share":"https://www.laohunote.com/m/news/1176538965?lang=zh_CN&edition=full","pubTime":"2021-09-09 16:06","market":"us","language":"en","title":"Most of China concepts stocks fell in premarket trading<blockquote>大多数中国概念股在盘前交易中下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176538965","media":"Tiger Newspress","summary":"(Sept 9)&nbsp;Most of China concepts stocks fell in premarket trading.","content":"<p>(Sept 9)&nbsp;Most of China concepts stocks fell in premarket trading.</p><p><blockquote>（9月9日）中国概念股盘前交易多数下跌。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1cc6e1e421893d8bebaea0dc552bf76\" tg-width=\"279\" tg-height=\"728\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Most of China concepts stocks fell in premarket trading<blockquote>大多数中国概念股在盘前交易中下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMost of China concepts stocks fell in premarket trading<blockquote>大多数中国概念股在盘前交易中下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-09 16:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Sept 9)&nbsp;Most of China concepts stocks fell in premarket trading.</p><p><blockquote>（9月9日）中国概念股盘前交易多数下跌。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1cc6e1e421893d8bebaea0dc552bf76\" tg-width=\"279\" tg-height=\"728\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176538965","content_text":"(Sept 9) Most of China concepts stocks fell in premarket trading.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815733937,"gmtCreate":1630718368829,"gmtModify":1631891082263,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Thanks ☺️&nbsp;","listText":"Thanks ☺️&nbsp;","text":"Thanks ☺️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/815733937","repostId":"2164803577","repostType":4,"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811277246,"gmtCreate":1630330605185,"gmtModify":1704958550263,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/811277246","repostId":"1182616475","repostType":4,"isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894762692,"gmtCreate":1628858205516,"gmtModify":1633688968611,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894762692","repostId":"1137098889","repostType":4,"repost":{"id":"1137098889","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628856721,"share":"https://www.laohunote.com/m/news/1137098889?lang=zh_CN&edition=full","pubTime":"2021-08-13 20:12","market":"us","language":"en","title":"Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137098889","media":"Tiger Newspress","summary":"The Dow and the S&P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beatin","content":"<p>The Dow and the S&amp;P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beating results, while signs of cooling inflation and a strong recovery in corporate earnings kept the indexes on track for a second straight week of gains.</p><p><blockquote>在华特-迪斯尼（Walt Disney）业绩超出预期后，道琼斯指数和标普500期货周五小幅创下历史新高，而通胀降温和企业盈利强劲复苏的迹象使这些指数有望连续第二周上涨。</blockquote></p><p> At 8:10 a.m. ET, Dow E-minis were up 59 points, or 0.17%, S&amp;P 500 E-minis were up 1.5 points, or 0.03% and Nasdaq 100 E-minis were down 17 points, or 0.11%.</p><p><blockquote>美国东部时间上午 8:10，道琼斯电子迷你指数上涨 59 点，即 0.17%，标普500电子迷你指数上涨 1.5 点，即 0.03%，纳斯达克 100 电子迷你指数下跌 17 点，即 0.11%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f7c31d72fc86500c83b0502d21899072\" tg-width=\"1172\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源：Tiger Trade，美国东部时间 08:10</span></p></blockquote></p><p> A stellar earnings season, improving economic data and the Senate’s passage of a large infrastructure bill have all reinforced investors’ belief in the economic recovery, pushing U.S. stocks to all-time highs in the past few sessions.</p><p><blockquote>出色的财报季、改善的经济数据以及参议院通过的一项大型基础设施法案都增强了投资者对经济复苏的信心，推动美国股市在过去几个交易日创下历史新高。</blockquote></p><p> Concerns over higher inflation and a sooner-than-anticipated policy tapering by the Federal Reserve also ebbed after data earlier this week showed the pace of increase in U.S. consumer prices slowed in July even as producer prices posted their biggest annual increase in more than a decade.</p><p><blockquote>本周早些时候的数据显示，尽管生产者价格创下十多年来最大年度涨幅，但美国7月份消费者价格涨幅放缓，对通胀上升和美联储提前缩减政策的担忧也有所减弱。</blockquote></p><p> Investors now await the minutes of the Fed’s latest policy meeting, due next week, and the annual meeting of central bankers in Jackson Hole, Wyoming, later in August for policy cues.</p><p><blockquote>投资者目前正在等待下周举行的美联储最新政策会议纪要，以及 8 月晚些时候在怀俄明州杰克逊霍尔举行的央行行长年会议纪要，以获取政策线索。</blockquote></p><p> <b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <a href=\"https://laohu8.com/S/DIS\">Walt Disney</a> – Walt Disney reported adjusted quarterly earnings of 80 cents per share, well above the 55-cent consensus estimate, with revenue beating forecasts as well. Disney’s performance was boosted by a rebound in U.S. theme park attendance as well as stronger-than-expected growth for its Disney+ streaming service. The company did, however, warn of uncertainty surrounding the impact of the delta coronavirus variant. Disney shares rallied 5.5% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/DIS\">华特·迪士尼</a>– 华特迪士尼公布调整后季度收益为每股 80 美分，远高于 55 美分的市场普遍预期，收入也超出预期。迪士尼的业绩得益于美国主题公园游客量的反弹以及其 Disney+ 流媒体服务的增长强于预期。然而，该公司确实警告称，德尔塔新冠病毒变异毒株的影响存在不确定性。迪士尼股价盘前上涨 5.5%。</blockquote></p><p> <a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a> – Airbnb lost 11 cents per share for its latest quarter, smaller than the 47-cent loss that analysts were anticipating. Revenue exceeded estimates, nearly quadrupling from a year earlier as domestic travel rebounded from its pandemic lows. However, the company pointed to uncertainty surrounding the pandemic and the delta variant, and Airbnb shares slid 2.8% in premarket trading.</p><p><blockquote><a href=\"https://laohu8.com/S/ABNB\">爱彼迎公司。</a>– 爱彼迎最新季度每股亏损 11 美分，低于分析师预期的 47 美分。随着国内旅行从疫情低点反弹，收入超出预期，同比增长近四倍。然而，该公司指出疫情和德尔塔变异毒株的不确定性，爱彼迎股价在盘前交易中下跌 2.8%。</blockquote></p><p> <a href=\"https://laohu8.com/S/ME\">23andMe, Inc.</a> – The genetic research company reported revenue of $59 million in its first quarter as a public company, up 23% from a year ago, while reporting a smaller loss. 23andMe shares climbed 2.1% in premarket action.</p><p><blockquote><a href=\"https://laohu8.com/S/ME\">23andMe公司。</a>– 这家基因研究公司作为上市公司公布的第一季度收入为 5900 万美元，比去年同期增长 23%，但亏损幅度较小。23andMe 股价在盘前交易中上涨 2.1%。</blockquote></p><p> <a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash posted a quarterly loss of 30 cents per share, wider than the 20 cents that Wall Street had projected. However, the food delivery service’s revenue did beat estimates, with gross order volume up 70% from a year ago. DoorDash also raised its full-year guidance for gross order volume. DoorDash shares fell 4.2% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/DASH\">DoorDash公司。</a>– DoorDash 公布每股季度亏损 30 美分，高于华尔街预测的 20 美分。不过，这家送餐服务的收入确实超出了预期，订单总量比一年前增长了 70%。DoorDash 还上调了全年总订单量指引。DoorDash 股价在盘前下跌 4.2%。</blockquote></p><p> <a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies Inc.</a> – SoFi lost 48 cents per share for its second quarter, compared with analyst forecasts of a 6 cents per share loss. The digital financial services company’s revenue exceeded estimates, as membership more than doubled from a year earlier, but the stock tanked 9.6% in premarket action.</p><p><blockquote><a href=\"https://laohu8.com/S/SOFI\">索菲技术公司。</a>– SoFi 第二季度每股亏损 48 美分，而分析师预测每股亏损 6 美分。这家数字金融服务公司的收入超出了预期，会员人数比去年同期增加了一倍多，但其股价在盘前交易中下跌了 9.6%。</blockquote></p><p> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> ,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> ,<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> – The FDA authorized Covid-19 vaccine booster shots for immunocompromised people utilizing the Pfizer/BioNTech and Moderna vaccines. Pfizer added 0.2%, BioNTech climbed 2.4% and Moderna gained 2.3%.</p><p><blockquote><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>,<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>– FDA 授权使用辉瑞/BioNTech 和 Moderna 疫苗为免疫功能低下的人注射 Covid-19 疫苗加强针。辉瑞上涨 0.2%，BioNTech 上涨 2.4%，Moderna 上涨 2.3%。</blockquote></p><p> <a href=\"https://laohu8.com/S/ERJ\">Embraer SA</a> – The Brazilian jet maker posted its first recurring quarterly profit since the first quarter of 2018, as travel demand rebounded from the lowest levels of the pandemic. Shares jumped 3.6% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/ERJ\">巴西航空工业公司</a>– 随着旅行需求从疫情最低水平反弹，这家巴西喷气式飞机制造商公布了自 2018 年第一季度以来的首次经常性季度利润。盘前股价上涨 3.6%。</blockquote></p><p> <a href=\"https://laohu8.com/S/KSU\">Kansas City Southern</a> – Kansas City Southern rejected an improved takeover offer fromCanadian Pacific Railway(CP), saying it did not constitute a “superior proposal” to its agreement withCanadian National Railway(CNI). The Canadian Pacific offer is worth $27 billion compared to $29 billion for Canadian National, but Canadian Pacific feels its bid has a better chance of regulatory approval.</p><p><blockquote><a href=\"https://laohu8.com/S/KSU\">堪萨斯城南部</a>- 堪萨斯城南方公司拒绝了加拿大太平洋铁路公司（CP）提出的改进后的收购要约，称该要约并不构成其与加拿大国家铁路公司（CNI）达成的协议的 “优越要约”。加拿大太平洋航空的报价价值 270 亿美元，而加拿大国家航空的报价为 290 亿美元，但加拿大太平洋航空认为其报价获得监管部门批准的机会更大。</blockquote></p><p> <a href=\"https://laohu8.com/S/ZIP\">ZipRecruiter Inc.</a> – ZipRecruiter posted a quarterly loss of 55 cents per share, compared with a consensus estimate of a 22 cents per share loss. However, the online employment marketplace operator saw revenue well above Street forecasts and made upbeat comments about the remainder of 2021. ZipRecruiter surged 14.3% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/ZIP\">ZipRecruiter公司。</a>– ZipRecruiter 公布季度亏损为每股 55 美分，而市场普遍预期为每股亏损 22 美分。然而，这家在线就业市场运营商的收入远高于华尔街的预测，并对2021年剩余时间发表了乐观的评论。ZipRecruiter 在盘前飙升 14.3%。</blockquote></p><p></p><p> <a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a> – Rocket shares gained 5.4% in premarket action despite a miss on the top and bottom lines for the online mortgage platform operator. Rocket did see a surge in closed loan origination volume over a year ago and gave upbeat current-quarter guidance for a variety of metrics.</p><p><blockquote><a href=\"https://laohu8.com/S/RKT\">火箭公司</a>– 尽管在线抵押贷款平台运营商 Rocket 的营收和利润均有所下降，但其股价在盘前交易中上涨了 5.4%。Rocket 确实看到封闭式贷款发放量比一年前激增，并对各种指标给出了乐观的本季度指引。</blockquote></p><p> <a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a> – The e-commerce platform company’s stock tumbled 27.8% in the premarket, following top and bottom line misses for its latest quarter. The operator of wish.com said it saw slowing demand for its products, fewer users and active buyers, and higher costs.</p><p><blockquote><a href=\"https://laohu8.com/S/WISH\">上下文逻辑公司。</a>- 这家电子商务平台公司的股价在盘前暴跌 27.8%，原因是该公司最近一个季度的营收和利润均有所下降。wish.com 的运营商表示，其产品需求放缓，用户和活跃买家减少，成本上升。</blockquote></p><p> <a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> – The videogame maker’s stock added 1.1% in premarket trading after Citi upgraded it to “buy” from “neutral”, saying the current risk/reward profile looks favorable following the stock’s recent pullback.</p><p><blockquote><a href=\"https://laohu8.com/S/ATVI\">动视暴雪</a>- 这家视频游戏制造商的股票在盘前交易中上涨了 1.1%，此前花旗将其评级从 “中性 ”上调至 “买入 ”，称在该股最近的回调之后，目前的风险/回报状况看起来很有利。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的顶线</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-13 20:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The Dow and the S&amp;P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beating results, while signs of cooling inflation and a strong recovery in corporate earnings kept the indexes on track for a second straight week of gains.</p><p><blockquote>在华特-迪斯尼（Walt Disney）业绩超出预期后，道琼斯指数和标普500期货周五小幅创下历史新高，而通胀降温和企业盈利强劲复苏的迹象使这些指数有望连续第二周上涨。</blockquote></p><p> At 8:10 a.m. ET, Dow E-minis were up 59 points, or 0.17%, S&amp;P 500 E-minis were up 1.5 points, or 0.03% and Nasdaq 100 E-minis were down 17 points, or 0.11%.</p><p><blockquote>美国东部时间上午 8:10，道琼斯电子迷你指数上涨 59 点，即 0.17%，标普500电子迷你指数上涨 1.5 点，即 0.03%，纳斯达克 100 电子迷你指数下跌 17 点，即 0.11%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f7c31d72fc86500c83b0502d21899072\" tg-width=\"1172\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源：Tiger Trade，美国东部时间 08:10</span></p></blockquote></p><p> A stellar earnings season, improving economic data and the Senate’s passage of a large infrastructure bill have all reinforced investors’ belief in the economic recovery, pushing U.S. stocks to all-time highs in the past few sessions.</p><p><blockquote>出色的财报季、改善的经济数据以及参议院通过的一项大型基础设施法案都增强了投资者对经济复苏的信心，推动美国股市在过去几个交易日创下历史新高。</blockquote></p><p> Concerns over higher inflation and a sooner-than-anticipated policy tapering by the Federal Reserve also ebbed after data earlier this week showed the pace of increase in U.S. consumer prices slowed in July even as producer prices posted their biggest annual increase in more than a decade.</p><p><blockquote>本周早些时候的数据显示，尽管生产者价格创下十多年来最大年度涨幅，但美国7月份消费者价格涨幅放缓，对通胀上升和美联储提前缩减政策的担忧也有所减弱。</blockquote></p><p> Investors now await the minutes of the Fed’s latest policy meeting, due next week, and the annual meeting of central bankers in Jackson Hole, Wyoming, later in August for policy cues.</p><p><blockquote>投资者目前正在等待下周举行的美联储最新政策会议纪要，以及 8 月晚些时候在怀俄明州杰克逊霍尔举行的央行行长年会议纪要，以获取政策线索。</blockquote></p><p> <b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <a href=\"https://laohu8.com/S/DIS\">Walt Disney</a> – Walt Disney reported adjusted quarterly earnings of 80 cents per share, well above the 55-cent consensus estimate, with revenue beating forecasts as well. Disney’s performance was boosted by a rebound in U.S. theme park attendance as well as stronger-than-expected growth for its Disney+ streaming service. The company did, however, warn of uncertainty surrounding the impact of the delta coronavirus variant. Disney shares rallied 5.5% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/DIS\">华特·迪士尼</a>– 华特迪士尼公布调整后季度收益为每股 80 美分，远高于 55 美分的市场普遍预期，收入也超出预期。迪士尼的业绩得益于美国主题公园游客量的反弹以及其 Disney+ 流媒体服务的增长强于预期。然而，该公司确实警告称，德尔塔新冠病毒变异毒株的影响存在不确定性。迪士尼股价盘前上涨 5.5%。</blockquote></p><p> <a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a> – Airbnb lost 11 cents per share for its latest quarter, smaller than the 47-cent loss that analysts were anticipating. Revenue exceeded estimates, nearly quadrupling from a year earlier as domestic travel rebounded from its pandemic lows. However, the company pointed to uncertainty surrounding the pandemic and the delta variant, and Airbnb shares slid 2.8% in premarket trading.</p><p><blockquote><a href=\"https://laohu8.com/S/ABNB\">爱彼迎公司。</a>– 爱彼迎最新季度每股亏损 11 美分，低于分析师预期的 47 美分。随着国内旅行从疫情低点反弹，收入超出预期，同比增长近四倍。然而，该公司指出疫情和德尔塔变异毒株的不确定性，爱彼迎股价在盘前交易中下跌 2.8%。</blockquote></p><p> <a href=\"https://laohu8.com/S/ME\">23andMe, Inc.</a> – The genetic research company reported revenue of $59 million in its first quarter as a public company, up 23% from a year ago, while reporting a smaller loss. 23andMe shares climbed 2.1% in premarket action.</p><p><blockquote><a href=\"https://laohu8.com/S/ME\">23andMe公司。</a>– 这家基因研究公司作为上市公司公布的第一季度收入为 5900 万美元，比去年同期增长 23%，但亏损幅度较小。23andMe 股价在盘前交易中上涨 2.1%。</blockquote></p><p> <a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash posted a quarterly loss of 30 cents per share, wider than the 20 cents that Wall Street had projected. However, the food delivery service’s revenue did beat estimates, with gross order volume up 70% from a year ago. DoorDash also raised its full-year guidance for gross order volume. DoorDash shares fell 4.2% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/DASH\">DoorDash公司。</a>– DoorDash 公布每股季度亏损 30 美分，高于华尔街预测的 20 美分。不过，这家送餐服务的收入确实超出了预期，订单总量比一年前增长了 70%。DoorDash 还上调了全年总订单量指引。DoorDash 股价在盘前下跌 4.2%。</blockquote></p><p> <a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies Inc.</a> – SoFi lost 48 cents per share for its second quarter, compared with analyst forecasts of a 6 cents per share loss. The digital financial services company’s revenue exceeded estimates, as membership more than doubled from a year earlier, but the stock tanked 9.6% in premarket action.</p><p><blockquote><a href=\"https://laohu8.com/S/SOFI\">索菲技术公司。</a>– SoFi 第二季度每股亏损 48 美分，而分析师预测每股亏损 6 美分。这家数字金融服务公司的收入超出了预期，会员人数比去年同期增加了一倍多，但其股价在盘前交易中下跌了 9.6%。</blockquote></p><p> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> ,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> ,<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> – The FDA authorized Covid-19 vaccine booster shots for immunocompromised people utilizing the Pfizer/BioNTech and Moderna vaccines. Pfizer added 0.2%, BioNTech climbed 2.4% and Moderna gained 2.3%.</p><p><blockquote><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>,<a href=\"https://laohu8.com/S/MRNA\">现代公司。</a>– FDA 授权使用辉瑞/BioNTech 和 Moderna 疫苗为免疫功能低下的人注射 Covid-19 疫苗加强针。辉瑞上涨 0.2%，BioNTech 上涨 2.4%，Moderna 上涨 2.3%。</blockquote></p><p> <a href=\"https://laohu8.com/S/ERJ\">Embraer SA</a> – The Brazilian jet maker posted its first recurring quarterly profit since the first quarter of 2018, as travel demand rebounded from the lowest levels of the pandemic. Shares jumped 3.6% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/ERJ\">巴西航空工业公司</a>– 随着旅行需求从疫情最低水平反弹，这家巴西喷气式飞机制造商公布了自 2018 年第一季度以来的首次经常性季度利润。盘前股价上涨 3.6%。</blockquote></p><p> <a href=\"https://laohu8.com/S/KSU\">Kansas City Southern</a> – Kansas City Southern rejected an improved takeover offer fromCanadian Pacific Railway(CP), saying it did not constitute a “superior proposal” to its agreement withCanadian National Railway(CNI). The Canadian Pacific offer is worth $27 billion compared to $29 billion for Canadian National, but Canadian Pacific feels its bid has a better chance of regulatory approval.</p><p><blockquote><a href=\"https://laohu8.com/S/KSU\">堪萨斯城南部</a>- 堪萨斯城南方公司拒绝了加拿大太平洋铁路公司（CP）提出的改进后的收购要约，称该要约并不构成其与加拿大国家铁路公司（CNI）达成的协议的 “优越要约”。加拿大太平洋航空的报价价值 270 亿美元，而加拿大国家航空的报价为 290 亿美元，但加拿大太平洋航空认为其报价获得监管部门批准的机会更大。</blockquote></p><p> <a href=\"https://laohu8.com/S/ZIP\">ZipRecruiter Inc.</a> – ZipRecruiter posted a quarterly loss of 55 cents per share, compared with a consensus estimate of a 22 cents per share loss. However, the online employment marketplace operator saw revenue well above Street forecasts and made upbeat comments about the remainder of 2021. ZipRecruiter surged 14.3% in the premarket.</p><p><blockquote><a href=\"https://laohu8.com/S/ZIP\">ZipRecruiter公司。</a>– ZipRecruiter 公布季度亏损为每股 55 美分，而市场普遍预期为每股亏损 22 美分。然而，这家在线就业市场运营商的收入远高于华尔街的预测，并对2021年剩余时间发表了乐观的评论。ZipRecruiter 在盘前飙升 14.3%。</blockquote></p><p></p><p> <a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a> – Rocket shares gained 5.4% in premarket action despite a miss on the top and bottom lines for the online mortgage platform operator. Rocket did see a surge in closed loan origination volume over a year ago and gave upbeat current-quarter guidance for a variety of metrics.</p><p><blockquote><a href=\"https://laohu8.com/S/RKT\">火箭公司</a>– 尽管在线抵押贷款平台运营商 Rocket 的营收和利润均有所下降，但其股价在盘前交易中上涨了 5.4%。Rocket 确实看到封闭式贷款发放量比一年前激增，并对各种指标给出了乐观的本季度指引。</blockquote></p><p> <a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a> – The e-commerce platform company’s stock tumbled 27.8% in the premarket, following top and bottom line misses for its latest quarter. The operator of wish.com said it saw slowing demand for its products, fewer users and active buyers, and higher costs.</p><p><blockquote><a href=\"https://laohu8.com/S/WISH\">上下文逻辑公司。</a>- 这家电子商务平台公司的股价在盘前暴跌 27.8%，原因是该公司最近一个季度的营收和利润均有所下降。wish.com 的运营商表示，其产品需求放缓，用户和活跃买家减少，成本上升。</blockquote></p><p> <a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> – The videogame maker’s stock added 1.1% in premarket trading after Citi upgraded it to “buy” from “neutral”, saying the current risk/reward profile looks favorable following the stock’s recent pullback.</p><p><blockquote><a href=\"https://laohu8.com/S/ATVI\">动视暴雪</a>- 这家视频游戏制造商的股票在盘前交易中上涨了 1.1%，此前花旗将其评级从 “中性 ”上调至 “买入 ”，称在该股最近的回调之后，目前的风险/回报状况看起来很有利。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137098889","content_text":"The Dow and the S&P 500 futures inched to record highs on Friday after Walt Disney’s forecast-beating results, while signs of cooling inflation and a strong recovery in corporate earnings kept the indexes on track for a second straight week of gains.\nAt 8:10 a.m. ET, Dow E-minis were up 59 points, or 0.17%, S&P 500 E-minis were up 1.5 points, or 0.03% and Nasdaq 100 E-minis were down 17 points, or 0.11%.\n*Source From Tiger Trade, EST 08:10\nA stellar earnings season, improving economic data and the Senate’s passage of a large infrastructure bill have all reinforced investors’ belief in the economic recovery, pushing U.S. stocks to all-time highs in the past few sessions.\nConcerns over higher inflation and a sooner-than-anticipated policy tapering by the Federal Reserve also ebbed after data earlier this week showed the pace of increase in U.S. consumer prices slowed in July even as producer prices posted their biggest annual increase in more than a decade.\nInvestors now await the minutes of the Fed’s latest policy meeting, due next week, and the annual meeting of central bankers in Jackson Hole, Wyoming, later in August for policy cues.\nStocks making the biggest moves in the premarket:\nWalt Disney – Walt Disney reported adjusted quarterly earnings of 80 cents per share, well above the 55-cent consensus estimate, with revenue beating forecasts as well. Disney’s performance was boosted by a rebound in U.S. theme park attendance as well as stronger-than-expected growth for its Disney+ streaming service. The company did, however, warn of uncertainty surrounding the impact of the delta coronavirus variant. Disney shares rallied 5.5% in the premarket.\nAirbnb, Inc. – Airbnb lost 11 cents per share for its latest quarter, smaller than the 47-cent loss that analysts were anticipating. Revenue exceeded estimates, nearly quadrupling from a year earlier as domestic travel rebounded from its pandemic lows. However, the company pointed to uncertainty surrounding the pandemic and the delta variant, and Airbnb shares slid 2.8% in premarket trading.\n23andMe, Inc. – The genetic research company reported revenue of $59 million in its first quarter as a public company, up 23% from a year ago, while reporting a smaller loss. 23andMe shares climbed 2.1% in premarket action.\nDoorDash, Inc. – DoorDash posted a quarterly loss of 30 cents per share, wider than the 20 cents that Wall Street had projected. However, the food delivery service’s revenue did beat estimates, with gross order volume up 70% from a year ago. DoorDash also raised its full-year guidance for gross order volume. DoorDash shares fell 4.2% in the premarket.\nSoFi Technologies Inc. – SoFi lost 48 cents per share for its second quarter, compared with analyst forecasts of a 6 cents per share loss. The digital financial services company’s revenue exceeded estimates, as membership more than doubled from a year earlier, but the stock tanked 9.6% in premarket action.\nPfizer ,BioNTech SE ,Moderna, Inc. – The FDA authorized Covid-19 vaccine booster shots for immunocompromised people utilizing the Pfizer/BioNTech and Moderna vaccines. Pfizer added 0.2%, BioNTech climbed 2.4% and Moderna gained 2.3%.\nEmbraer SA – The Brazilian jet maker posted its first recurring quarterly profit since the first quarter of 2018, as travel demand rebounded from the lowest levels of the pandemic. Shares jumped 3.6% in the premarket.\nKansas City Southern – Kansas City Southern rejected an improved takeover offer fromCanadian Pacific Railway(CP), saying it did not constitute a “superior proposal” to its agreement withCanadian National Railway(CNI). The Canadian Pacific offer is worth $27 billion compared to $29 billion for Canadian National, but Canadian Pacific feels its bid has a better chance of regulatory approval.\nZipRecruiter Inc. – ZipRecruiter posted a quarterly loss of 55 cents per share, compared with a consensus estimate of a 22 cents per share loss. However, the online employment marketplace operator saw revenue well above Street forecasts and made upbeat comments about the remainder of 2021. ZipRecruiter surged 14.3% in the premarket.\nRocket Companies – Rocket shares gained 5.4% in premarket action despite a miss on the top and bottom lines for the online mortgage platform operator. Rocket did see a surge in closed loan origination volume over a year ago and gave upbeat current-quarter guidance for a variety of metrics.\nContextLogic Inc. – The e-commerce platform company’s stock tumbled 27.8% in the premarket, following top and bottom line misses for its latest quarter. The operator of wish.com said it saw slowing demand for its products, fewer users and active buyers, and higher costs.\nActivision Blizzard – The videogame maker’s stock added 1.1% in premarket trading after Citi upgraded it to “buy” from “neutral”, saying the current risk/reward profile looks favorable following the stock’s recent pullback.","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895130647,"gmtCreate":1628727637589,"gmtModify":1633744827143,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"themes":[],"title":"","htmlText":"Need support to more online 😬","listText":"Need support to more online 😬","text":"Need support to more online 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/895130647","repostId":"2158845236","repostType":4,"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}